0000930413-18-001993.txt : 20180611 0000930413-18-001993.hdr.sgml : 20180611 20180611172446 ACCESSION NUMBER: 0000930413-18-001993 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20180430 FILED AS OF DATE: 20180611 DATE AS OF CHANGE: 20180611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZO BIOCHEM INC CENTRAL INDEX KEY: 0000316253 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 132866202 STATE OF INCORPORATION: NY FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09974 FILM NUMBER: 18892866 BUSINESS ADDRESS: STREET 1: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: 5167555500 MAIL ADDRESS: STREET 1: ENZO BIOCHEM INC STREET 2: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 10-Q 1 c91227_10q.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Mark one

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number 001-09974

	ENZO BIOCHEM, INC.
	(Exact name of registrant as specified in its charter)

New York		13-2866202
(State or Other Jurisdiction of Incorporation or Organization)		(IRS. Employer Identification No.)

527 Madison Ave, New York, New York		10022
(Address of Principal Executive office)		(Zip Code)

212-583-0100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 45 of Regulation S-T (§232.405 of that chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer o		Accelerated filer x
Non-accelerated filer o	(Do not check if smaller reporting company)	Smaller reporting company o
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Yes o No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes o No x

As of June 1, 2018, the Registrant had 47,165,942 shares of common stock outstanding.

ENZO BIOCHEM, INC.
FORM 10-Q
April 30, 2018

INDEX

PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements	3

	Consolidated Balance Sheets – April 30, 2018 (unaudited) and July 31, 2017	3

	Consolidated Statements of Operations for the three and nine months ended April 30, 2018 and 2017 (unaudited)	4

	Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended April 30, 2018 and 2017 (unaudited)	5

	Consolidated Statement of Stockholders’ Equity for the nine months ended April 30, 2018 (unaudited)	6

	Consolidated Statements of Cash Flows for the nine months ended April 30, 2018 and 2017 (unaudited)	7

	Notes to the Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30

Item 4.	Controls and Procedures	31

Part II – OTHER INFORMATION

Item 1.	Legal Proceedings	32

Item 1A.	Risk Factors	32

Item 6.	Exhibits	32

Signatures		32

Part 1 Financial Information

Item 1 Financial Statements

ENZO BIOCHEM, INC.

CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

	April 30, 2018 (unaudited)			July 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	62,556		$	64,167
Accounts receivable, net of allowances		14,407			15,180
Inventories		7,278			7,047
Prepaid expenses and other		2,175			2,690
Total current assets		86,416			89,084

Property, plant and equipment, net		7,953			7,901
Goodwill		7,452			7,452
Intangible assets, net		2,149			2,895
Other assets		1,481			333
Total assets	$	105,451		$	107,665

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable – trade	$	8,250		$	10,350
Accrued liabilities		9,795			6,720
Other current liabilities		623			740
Total current liabilities		18,668			17,810

Other liabilities		404			983
Total liabilities	$	19,072		$	18,793

Commitments and contingencies

Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding		—			—
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 47,161,942 at April 30, 2018 and 46,506,176 at July 31, 2017		472			465
Additional paid-in capital		330,517			328,294
Accumulated deficit		(246,457	)		(241,900	)
Accumulated other comprehensive income		1,847			2,013
Total stockholders’ equity		86,379			88,872
Total liabilities and stockholders’ equity	$	105,451		$	107,665

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(in thousands, except per share data)

	Three Months Ended April 30,						Nine Months Ended April 30,
	2018			2017			2018			2017
Revenues:
Clinical laboratory services	$	18,137		$	19,584		$	58,001		$	56,979
Product revenues		7,415			7,312			21,618			21,721
Royalty and license fee income		78			193			639			933
Total revenues		25,630			27,089			80,258			79,633

Operating costs and expenses:
Cost of clinical laboratory services		10,995			11,334			34,767			33,282
Cost of product revenues		3,562			3,582			10,828			10,411
Research and development		799			766			2,358			2,071
Selling, general and administrative		11,025			10,534			32,986			33,246
Provision for uncollectible accounts receivable		396			620			1,989			1,968
Legal fee expense		1,651			512			3,782			1,254
Total operating costs and expenses		28,428			27,348			86,710			82,232

Operating loss		(2,798	)		(259	)		(6,452	)		(2,599	)

Other income (expense):
Interest		227			115			569			240
Other		17			(74	)		86			69
Foreign exchange gain (loss)		(462	)		147			143			(308	)
Loss before income taxes		(3,016	)		(71	)		(5,654	)		(2,598	)
Benefit for income taxes		—			—			1,097			—
Net loss	$	(3,016	)	$	(71	)	$	(4,557	)	$	(2,598	)

Net loss per common share:
Basic and diluted	$	(0.06	)	$	(0.00	)	$	(0.10	)	$	(0.06	)

Weighted average common shares outstanding:
Basic and diluted		47,073			46,367			46,895			46,310

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(in thousands)

	Three Months Ended April 30,						Nine Months Ended April 30,
	2018			2017			2018			2017
Net loss	$	(3,016	)	$	(71	)	$	(4,557	)	$	(2,598	)
Other comprehensive income (loss):
Foreign currency translation adjustments		329			(116	)		(166	)		122
Comprehensive loss	$	(2,687	)	$	(187	)	$	(4,723	)	$	(2,476	)

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
Nine Months Ended April 30, 2018
(UNAUDITED)
(in thousands, except share data)

	Common Stock Shares Issued		Treasury Stock Shares			Common Stock Amount		Additional Paid-in Capital			Treasury Stock Amount			Accumulated Deficit			Accumulated Other Comprehensive Income			Total Stockholders’ Equity
Balance at July 31, 2017		46,506,176		—		$	465	$	328,294		$	—		$	(241,900	)	$	2,013		$	88,872

Net loss for the period ended April 30, 2018		—		—			—		—			—			(4,557	)		—			(4,557	)

Cashless options exercise		340,898		106,911			4		1,010			(1,014	)		—			—			—

Vesting of restricted stock		2,562					—		—			—			—			—			—

Exercise of stock options		274,726		—			3		828			—			—			—			831
Share-based compensation charges		—		—			—		617			—			—			—			617

Issuance of common stock and treasury stock for employee 401(k) plan match		37,580		(106,911	)		—		(232	)		1,014			—			—			782

Foreign currency translation adjustments		—		—			—		—			—			—			(166	)		(166	)

Balance at April 30, 2018		47,161,942		—		$	472	$	330,517		$	—		$	(246,457	)	$	1,847		$	86,379

The accompanying notes are an integral part of these consolidated financial statements

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)

	Nine Months Ended April 30,
	2018			2017
Cash flows from operating activities:
Net loss	$	(4,557	)	$	(2,598	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment		1,608			1,552
Amortization of intangible assets		742			1,140
Provision for uncollectible accounts receivable		1,989			1,968
Share-based compensation charges		617			601
Accrual for share-based 401(k) employer match expense		630			552
Foreign exchange (gain) loss		(149	)		267

Changes in operating assets and liabilities:
Accounts receivable		(1,233	)		(3,192	)
Inventories		(257	)		(213	)
Prepaid expenses and other		513			195
Accounts payable – trade		(2,126	)		(459	)
Accrued liabilities, other current liabilities and other liabilities		2,846			(1,707	)
Other assets		(1,098	)		—
Total adjustments		4,082			704

Net cash used in operating activities		(475	)		(1,894	)

Cash flows from investing activities:
Capital expenditures		(1,626	)		(1,424	)
Security deposits and other		(51	)		6
Net cash used in investing activities		(1,677	)		(1,418	)

Cash flows from financing activities:
Proceeds from borrowings under Credit Agreement		—			40,694
Repayments under Credit Agreement		—			(42,250	)
Installment loan and capital lease obligation payments		(299	)		(428	)
Proceeds from exercise of stock options		831			159
Net cash provided by (used in) financing activities		532			(1,825	)

Effect of exchange rate changes on cash and cash equivalents		9			(13	)

Decrease in cash and cash equivalents		(1,611	)		(5,150	)
Cash and cash equivalents - beginning of period		64,167			67,777
Cash and cash equivalents - end of period	$	62,556		$	62,627

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of April 30, 2018
(Unaudited)
(Dollars in thousands, except share data)

Note 1 – Basis of Presentation

The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of April 30, 2018, the consolidated statements of operations and comprehensive income (loss) for the three and nine month ended April 30, 2018 and 2017, the consolidated statements of cash flows for the nine months ended April 30, 2018 and 2017 and the consolidated statement of stockholders’ equity for the nine months ended April 30, 2018 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2017 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2017 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2018.

Effect of New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires all excess tax benefits or deficiencies to be recognized as income tax expense or benefit in the income statement. In addition, excess tax benefits should be classified along with other income tax cash flows as an operating activity in the statement of cash flows. We adopted this standard as of August 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial statements.

Pronouncements Issued but Not Yet Adopted

In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606. ASU 2014-09 and its amendments supersede the current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue recognition standard is to require an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled to in exchange for the goods or services it transfers control of to its customers.

The standard will be effective for our fiscal year beginning August 1, 2018 and its interim periods. We are not early adopting. We expect to use the full retrospective method upon adoption by applying the standard to each prior reporting period presented. We continue to evaluate the expected impact of the standard. Based on our preliminary assessment of the standard, we expect that the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be considered an implicit price concession in determining net revenues. Accordingly, we expect to report the estimate of uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within operating costs and expenses.

The adoption of this standard will also result in increased disclosure, including qualitative and quantitative disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts from customers. However, the adoption of this standard is not expected to have a material impact on our financial position or cash flows.

In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for our fiscal year beginning August 1, 2019 including interim periods within that fiscal year. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available.

We believe the adoption of this standard would materially impact our consolidated financial statements by significantly increasing our non-current assets and non-current liabilities on our consolidated balance sheets if we record the right of use assets and related lease liabilities for our existing operating leases.

We will recognize expense in the consolidated statement of operations similar to current lease accounting, in the cost of sales and selling, general and administrative.

In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326). This standard changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a new forward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoption of this standard is required for our annual and interim periods beginning August 1, 2020 and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial position and cash flows.

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption of this standard is required for our annual and interim periods beginning August 1, 2018 with the amendments in the update applied prospectively to an award modified on or after the adoption date.

In May 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, regarding the accounting implications of the recently issued Tax Cuts and Jobs Act (the “Act”). This standard is effective immediately. The update clarifies that in a company’s financial statements that include the reporting period in which the Act was enacted, the company must first reflect the income tax effects of the Act in which the accounting under GAAP is complete. These amounts would not be provisional amounts. The company would also report provisional amounts for those specific income tax effects for which the accounting under GAAP is incomplete but a reasonable estimate can be determined. We have recorded a provisional amount which we believe is a reasonable estimate of the effects of the Act on our financial statements as of April 30, 2018. Technical corrections or other forthcoming guidance could change how we interpret provisions of the Act, which may impact our effective tax rate and could affect our deferred tax assets, tax positions and/or our tax liabilities.

We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations.

Concentration Risk

Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 40% and 38% of the Clinical Labs segment net revenue for the three months ended April 30, 2018 and 2017 respectively, and 39% and 38% for the nine months ended April 30, 2018 and 2017, respectively.

Note 2 – Net income (loss) per share

Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three and nine months ended April 30, 2018 and 2017 diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive.

For the three and nine months ended April 30, 2018, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 431,000 and 694,000, respectively, because their effect would be antidilutive. For the three and nine months ended April 30, 2017, approximately 987,000 and 865,000 weighted average stock options were excluded from the calculation of diluted weighted average shares outstanding because their effect would be antidilutive.

For the three and nine months ended April 30, 2018, the effect of approximately 581,000 and 194,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and nine months ended April 30, 2017, the effect of approximately zero and 165,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Note 3 - Supplemental disclosure for statement of cash flows

For the nine months ended April 30, 2018 and 2017, income taxes paid by the Company were $65 and $1,021, respectively.

For the nine months ended April 30, 2018 and 2017, interest paid by the Company was $61 and $99, respectively.

For the nine months ended April 30, 2018 and 2017, the Company financed $0 and $69 respectively, in machinery and transportation equipment under installment loans.

During the nine months ended April 30, 2018 certain officers of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares, as treasury stock.

During the nine months ended April 30, 2018, the Company contributed its treasury stock and issued common stock in connection with its share-based 401(k) employer match in the amount of $782. For the 2017 period, the Company issue shares of common stock in the amount of $724.

Note 4 – Inventories

Inventories consist of the following:

	April 30, 2018		July 31, 2017
Raw materials	$	817	$	852
Work in process		2,065		1,905
Finished products		4,396		4,290
	$	7,278	$	7,047

Note 5 – Goodwill and intangible assets

At April 30, 2018 and July 31, 2017, the Company’s carrying amount of goodwill, related to the Clinical Labs segment, is $7,452.

The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows:

	Gross		Accumulated Amortization			Net
July 31, 2017	$	27,436	$	(24,541	)	$	2,895
Amortization expense		—		(742	)		(742	)
Foreign currency translation		2		(6	)		(4	)
April 30, 2018	$	27,438	$	(25,289	)	$	2,149

Intangible assets, all finite lived, consist of the following:

	April 30, 2018							July 31, 2017
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Patents	$	11,027	$	(10,971	)	$	56	$	11,027	$	(10,951	)	$	76
Customer relationships		11,892		(9,799	)		2,093		11,881		(9,083	)		2,798
Website and acquired content		1,010		(1,010	)		—		1,011		(1,011	)		—
Licensed technology and other		492		(492	)		—		484		(463	)		21
Trademarks		3,017		(3,017	)		—		3,033		(3,033	)		—
Total	$	27,438	$	(25,289	)	$	2,149	$	27,436	$	(24,541	)	$	2,895

At April 30, 2018, information with respect to intangibles assets acquired is as follows:

	Useful life assigned	Weighted average remaining useful life
Customer relationships	8 -15 years	2.5 years
Other intangibles	10 years	1.5 years

At April 30, 2018, the weighted average remaining useful life of intangible assets is approximately two years.

Note 6 – Accrued Liabilities

Accrued liabilities consist of the following:

	April 30, 2018		July 31, 2017
Payroll, benefits, and commissions	$	4,343	$	4,092
Legal fee expense		2,401		599
Professional fees		764		442
Research and development		—		143
Other		2,287		1,444
	$	9,795	$	6,720

At April 30, 2018, other accrued liabilities primarily include $400 for a legal settlement.

Note 7 – Other Liabilities

Other liabilities consist of the following:

	April 30, 2018		July 31, 2017
Capital lease obligations, net of short term	$	397	$	551
Accrued legal settlement		—		410
Installment loans, net of short term		7		22
	$	404	$	983

As of April 30, 2018, future minimum payments under the capital leases, net of interest of $75 aggregates $570 including a short term debt portion of $173 included in other current liabilities. Future minimum payments under the installment loans aggregate $44, including a short term portion of $37 included in other current liabilities.

Note 8 – Stockholders’ Equity

Controlled Equity Offering

The Company has a Controlled Equity Offering^SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The initial agreement contemplated the sale of shares of the Company’s common stock having an aggregate offering price of up to $20.0 million. In December 2014, the Sales Agreement was amended in order for the Company to offer and sell additional shares of Common Stock having an aggregate offering price of $20.0 million.

On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017.

During the nine months ended April 30, 2018 and during fiscal 2017, the Company did not sell any shares of Common Stock under the Sales Agreement.

Treasury stock

During the nine months ended April 30, 2018, certain officers of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares, as treasury stock. All of the treasury shares were used in the share-based 401(k) employer match made during the nine months ended April 30, 2018.

Share-based compensation

The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Plan”). The 2011 Incentive Plan, which is the only plan from which awards may be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards.

At the 2017 annual meeting, shareholders approved the amendment and restatement of the 2011 Plan, including an increase in the number of shares of common stock authorized for grant under the 2011 Plan, from 3 million shares to 5 million shares.

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended April 30,				Nine months ended April 30,
	2018		2017		2018		2017
Stock options	$	202	$	204	$	609	$	586
Restricted stock		2		5		8		15
	$	204	$	209	$	617	$	601

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended April 30,				Nine months ended April 30,
	2018		2017		2018		2017
Cost of clinical laboratory services	$	—	$	2	$	—	$	5
Selling, general and administrative		204		207		617		596
	$	204	$	209	$	617	$	601

No excess tax benefits were recognized during the nine month periods ended April 30, 2018 and 2017.

Stock Option Plans

The following table summarizes stock option activity during the nine month period ended April 30, 2018:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2017		2,130,995		$	4.26
Awarded		117,580		$	8.36
Exercised		(615,624	)	$	2.99		$	5,896
Cancelled or expired		(29,334	)	$	5.94
Outstanding at end of period		1,603,617		$	5.02	2.6 years	$	4,344
Exercisable at end of period		1,168,489		$	4.25	1.2 years	$	2,261

As of April 30, 2018, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.9 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is fourteen months.

The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options.

Restricted Stock Awards

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2017		7,436		$	4.45
Awarded		—			—
Vested		(2,562	)	$	(5.51	)
Forfeited		(386	)		(5.62	)
Unvested at end of period		4,488		$	2.97

The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2018, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately twenty-two months.

The fair value of the awards that vested during the nine months ended April 30, 2018 and 2017 was $22 and $19, respectively.

The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 2,266,800 shares as of April 30, 2018.

During the nine months ended April 30, 2018, the Company contributed $782 to match its employees’ 401(k) contributions with 106,911 shares of treasury stock and by issuing 37,580 shares of its common stock, representing the fair value of the shares at the match date, and adjusted treasury stock, common stock and additional paid in capital by the same amount.

During the nine months ended April 30, 2017, the Company contributed $724 to match its employees’ 401(k) contributions by issuing 91,541 shares of its common stock, representing the fair value of the shares at the match date, and adjusted common stock and additional paid in capital by the same amount.

Note 9 – Income taxes

On December 22, 2017, legislation commonly known as the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017.

The Company calculated its best estimate of the impact of the Act in accordance with its understanding of the Act and guidance available as of the date of this filing and recorded $1.1 million as an income tax benefit in the nine months ended April 30, 2018, the period in which the legislation was enacted, related to a credit for alternative minimum taxes (AMT) paid in prior periods. A provisional amount related to the remeasurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was fully offset by an equivalent adjustment to the deferred tax valuation allowance. No provisional amount related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings was deemed necessary.

On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In accordance with SAB 118, the Company has determined that the $1.1 million income tax benefit, which relates to the AMT credit, is a provisional amount and a reasonable estimate at April 30, 2018.

benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.

Note 10 – Segment reporting

The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Therapeutic segment conducts research and development activities for therapeutic drug candidates.

The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. When recognized, legal settlements, net represents activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the patents or products covered by the settlements.

Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2017.

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2018

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,137			—			—			—		$	18,137
Product revenues		—		$	7,415			—			—			7,415
Royalty and license fee income		—			78			—			—			78
		18,137			7,493			—			—			25,630
Operating costs and expenses:
Cost of clinical laboratory services		10,995			—			—			—			10,995
Cost of product revenues		—			3,562			—			—			3,562
Research and development		—			576		$	223			—			799
Selling, general and administrative		6,252			2,974			—		$	1,799			11,025
Provision for uncollectible accounts receivable		400			(4	)		—			—			396
Legal fee expense		25			19			—			1,607			1,651
Total operating costs and expenses		17,672			7,127			223			3,406			28,428

Operating income (loss)		465			366			(223	)		(3,406	)		(2,798	)

Other income (expense):
Interest		(22	)		12			—			237			227
Other		15			2			—			—			17
Foreign exchange loss		—			(462	)		—			—			(462	)
Income (loss) before income taxes	$	458		$	(82	)	$	(223	)	$	(3,169	)	$	(3,016	)

Depreciation and amortization included above	$	437		$	358		$	—		$	20		$	815

Share-based compensation included in above:
Selling, general and administrative		26		$	17			—		$	161			204
Total	$	26		$	17		$	—		$	161		$	204

Capital expenditures	$	465		$	96		$	—		$	—		$	561

Three months ended April 30, 2017

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	19,584			—			—			—		$	19,584
Product revenues		—		$	7,312			—			—			7,312
Royalty and license fee income		—			193			—			—			193
		19,584			7,505			—			—			27,089
Operating costs and expenses:
Cost of clinical laboratory services		11,334			—			—			—			11,334
Cost of product revenues		—			3,582			—			—			3,582
Research and development		—			552		$	214			—			766
Selling, general and administrative		6,118			2,745			—		$	1,671			10,534
Provision for uncollectible accounts receivable		650			(30	)		—			—			620
Legal fee expense		4			42			—			466			512
Total operating costs and expenses		18,106			6,891			214			2,137			27,348

Operating income (loss)		1,478			614			(214	)		(2,137	)		(259	)

Other income (expense):
Interest		(28	)		12			—			131			115
Other		7			(98	)		—			17			(74	)
Foreign exchange gain		—			147			—			—			147
Income (loss) before income taxes	$	1,457		$	675		$	(214	)	$	(1,989	)	$	(71	)

Depreciation and amortization included above	$	390		$	423		$	—		$	37		$	850

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Selling, general and administrative		38		$	23			—		$	146			207
Total	$	40		$	23		$	—		$	146		$	209

Capital expenditures	$	483		$	252		$	—		$	—		$	735

Nine months ended April 30, 2018

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	58,001			—			—			—		$	58,001
Product revenues		—		$	21,618			—			—			21,618
Royalty and license fee income		—			639			—			—			639
		58,001			22,257			—			—			80,258
Operating costs and expenses:
Cost of clinical laboratory services		34,767			—			—			—			34,767
Cost of product revenues		—			10,828			—			—			10,828
Research and development		—			1,690		$	668			—			2,358
Selling, general and administrative		18,454			8,487			—		$	6,045			32,986
Provision for uncollectible accounts receivable		2,000			(11	)		—			—			1,989
Legal fee expense		46			47			—			3,689			3,782
Total operating costs and expenses		55,267			21,041			668			9,734			86,710

Operating income (loss)		2,734			1,216			(668	)		(9,734	)		(6,452	)

Other income (expense):
Interest		(70	)		35			—			604			569
Other		32			10			—			44			86
Foreign exchange gain		—			143			—			—			143
Income (loss) before income taxes	$	2,696		$	1,404		$	(668	)	$	(9,086	)	$	(5,654	)

Depreciation and amortization included above	$	1,254		$	1,039		$	—		$	57		$	2,350

Share-based compensation included in above:
Selling, general and administrative		86		$	61			—		$	470			617
Total	$	86		$	61		$	—		$	470		$	617

Capital expenditures	$	1,459		$	167		$	—		$	—		$	1,626

Nine months ended April 30, 2017

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	56,979			—			—			—		$	56,979
Product revenues		—		$	21,721			—			—			21,721
Royalty and license fee income		—			933			—			—			933
		56,979			22,654			—			—			79,633
Operating costs and expenses:
Cost of clinical laboratory services		33,282			—			—			—			33,282
Cost of product revenues		—			10,411			—			—			10,411
Research and development		—			1,695		$	376			—			2,071
Selling, general and administrative		17,967			8,596			—		$	6,683			33,246
Provision for uncollectible accounts receivable		1,910			58			—			—			1,968
Legal fee expense		105			70			—			1,079			1,254
Total operating costs and expenses		53,264			20,830			376			7,762			82,232

Operating income (loss)		3,715			1,824			(376	)		(7,657	)		(2,599	)

Other income (expense):
Interest		(85	)		34			—			291			240
Other		126			(98	)		—			41			69
Foreign exchange loss		—			(308	)		—			—			(308	)
Income (loss) before income taxes	$	3,756		$	1,452		$	(376	)	$	(7,430	)	$	(2,598	)

Depreciation and amortization included above	$	1,185		$	1,432		$	—		$	75		$	2,692

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Selling, general and administrative		74		$	49			—		$	473			596
Total	$	79		$	49		$	—		$	473		$	601

Capital expenditures	$	1,070		$	354		$	—		$	—		$	1,424

Note 11 – Contingencies

The Company is engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. In December 2013, the Court granted in part and denied in part Roche’s summary judgment motion. In October 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by the end of January 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On October 2, 2017, the Court issued its claim construction ruling. On May 11, 2018, the Court issued a revised scheduling order which required the completion of expert discovery by July 13, 2018 and scheduled a conference on August 17, 2018 that will function as a pre-trial conference or a pre-motion conference. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them.

There are seven pending cases originally brought by the Company in the United States District Court for the District of Delaware (“the Court”) alleging patent infringement against various companies. On June 28, 2017, the Court issued an opinion in the Gen-Probe case, granting Gen-Probe’s motion for summary judgment that the asserted claims of the ’180 patent are invalid for nonenablement. The Court entered final judgment of invalidity of the asserted claims of the ‘180 patent on July 19, 2017 in the Gen-Probe and Hologic cases. The Court entered partial final judgment of invalidity of the asserted claims of the ‘180 patent and stayed the remainder of the cases in the Becton Dickinson and Roche cases on July 31, 2017 and August 2, 2017, respectively. The Company filed notices of appeal in each of the Gen-Probe, Hologic, Becton Dickinson, and Roche cases, which were docketed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). In the Abbott case, the parties agreed that the Court’s summary judgment ruling in the Gen-Probe case invalidated all of the ’180 patent claims asserted against the Abbott Defendants. On August 15, 2017, the Court granted Abbott’s motion for summary judgment that the asserted claims of the ’405 patent are invalid for nonenablement. On September 1, 2017, the Court entered final judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents for nonenablement in the Abbott case. Enzo subsequently filed a notice of appeal in the Abbott case on September 14, 2017. The Federal Circuit docketed the appeal on September 15, 2017. The Federal Circuit consolidated the appeals from the Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche litigations (“Consolidated Appeals”). We disagree with the Court’s invalidity decisions regarding the ‘180 and ‘405 patents in the pending cases as set forth in our opening brief in the Consolidated Appeals pending in the Federal Circuit filed on November 28, 2017. In the Consolidated Appeals, we have asked the Federal Circuit to reverse the Court’s grants of final and summary judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents and to remand the cases against Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche to the Court. Briefing is now complete in the Consolidated Appeals. The parties await the Federal Circuit’s scheduling of an oral argument date for the Consolidated Appeals. In the other two cases involving Hologic, one of the cases is stayed (Hologic II), while the other case (Hologic III) that involves the ‘581 patent is proceeding under the Court’s scheduling order with fact and expert discovery deadlines through September 2018, a summary judgment hearing date in April 2019, and a trial date in September 2019. In Hologic III, the Court granted Enzo’s motion to amend its complaint to add two new defendants, Grifols Diagnostic Solutions, Inc. and Grifols, S.A, to that case. Grifols, S.A. has moved to dismiss for lack of personal jurisdiction; briefing on that motion is complete but the Court has not set a date for oral argument. The parties have completed claim construction briefing, and a claim construction hearing is scheduled for July 2, 2018. Regarding Hologic’s petition requesting institution of an inter partes review proceeding regarding the U.S Patent No. 6,221,581 (“the ‘581 patent”) filed with the United States Patent and Trademark Office (“PTO”), the Patent Trial and Appeals Board (“the Board”) denied institution of Hologic’s petition on April 18, 2018. On May 18, 2018, Hologic filed with the Board a request for rehearing of the order denying institution of inter partes review of the ‘581 patent. Enzo has requested permission to file a brief in response to Hologic’s request for rehearing.

There can be no assurance that the Company will be successful in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company.

The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes and other information included elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

Our disclosure and analysis in this report, including but not limited to the information discussed in this Item 2, contain forward-looking information about our Company’s financial results and estimates, business prospects and products in research and development that involve substantial risks and uncertainties. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “will”, and other words and terms of similar meaning in connection with any discussion of future operations or financial performance.

In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign currency rates, intellectual property matters, the outcome of contingencies, such as legal proceedings, and financial results. We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. As a result, investors are cautioned not to place undue reliance on any of our forward-looking statements. Investors should bear this in mind as they consider forward-looking statements. We do not assume any obligation to update or revise any forward-looking statement that we make, even if new information becomes available or other events occur in the future. We are also affected by other factors that may be identified from time to time in our filings with the Securities and Exchange Commission, some of which are set forth in Item 1A - Risk Factors in our Form 10-K filing for the July 31, 2017 fiscal year. You are advised to consult any further disclosures we make on related subjects in our Forms 10-Q, 8-K and 10-K reports to the Securities and Exchange Commission. Although we have attempted to provide a list of important factors which may affect our business, investors are cautioned that other factors may prove to be important in the future and could affect our operating results.

You should understand that it is not possible to predict or identify all such factors or to assess the impact of each factor or combination of factors on our business. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Overview

Enzo Biochem, Inc. (the “Company” “we”, “our” or “Enzo”) is an integrated diagnostic bioscience company focusing on delivering and applying advanced technology capabilities to produce affordable reliable products and services to allow our customers to meet their clinical needs. We develop, manufacture and sell our proprietary technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. Enzo’s structure and business strategy represent the culmination of years of extensive planning and work. The Company now has the unique ability to offer low cost, high performance products and services in molecular diagnostics, which ideally positions it to capitalize on the reimbursement pressures facing diagnostic labs. Our pioneering work in genomic analysis coupled with our extensive patent estate and enabling platforms have positioned the Company to continue to play an important role in the rapidly growing molecular medicine marketplaces.

Enzo technology solutions and platforms and unique operational structure are designed to reduce overall healthcare costs for both government and private insurers. Our proprietary technology platforms reduces our customers’ need for multiple, specialized instruments, and offer a variety of high throughput capabilities together with a demonstrated high level of accuracy and reproducibility. Our genetic test panels are focused on large and growing markets primarily in the areas of personalized medicine, women’s health, infectious diseases and genetic disorders.

For example, our AMPIPROBE® technology platform can lead to the development of an entire line of nucleic acid clinical products that can allow laboratories to offer a complete menu of services at a cost that allows them to enjoy an acceptable margin. Our technology solutions provide tools to physicians, clinicians and other health care providers to improve detection, treatment and monitoring of a broad spectrum of diseases and conditions. In addition, reduced patient to physician office visits translates into lower healthcare processing costs and greater patient services.

In the course of our research and development activities, we have built a substantial portfolio of intellectual property assets, comprised of 336 issued patents worldwide, and over 151 pending patent applications, along with extensive enabling technologies and platforms.

Below are brief descriptions of each of our operating segments (See Note 10 in the Notes to Consolidated Financial Statements):

Enzo Clinical Labs is a clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Company believes having a CLIA-certified and a College of American Pathologists (“CAP”) accredited medical laboratory located in New York provides us the opportunity to more rapidly introduce cutting edge products and services to the clinical marketplace. Enzo Clinical Labs offers an extensive menu of molecular and other clinical laboratory tests and procedures used in patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. Our laboratory is equipped with state-of-the-art communication and connectivity solutions enabling the rapid transmission, analysis and interpretation of generated data. We operate a full service clinical laboratory in Farmingdale, New York, a network of over 30 patient service centers throughout New York, New Jersey and expanding into Connecticut, a free standing “STAT” or rapid response laboratory in New York City and a full service phlebotomy, in-house logistics department, and an information technology department. Given our license in New York State, we are able to offer testing services to clinical laboratories and physicians in the majority of states nationwide.

Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers worldwide. Underpinned by broad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories around the world. Information regarding our technologies can be found in the “Core Technologies” section (See Form 10K for the fiscal year ended July, 31, 2017). We are internationally recognized and acknowledged as a leader in the development, manufacturing validation and commercialization of numerous products serving not only the clinical research market but life sciences researchers in the fields of cellular analysis and drug discovery, among others. Our operations are supported by global operations allowing for the efficient marketing and delivery of our products around the world.

Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. Enzo Therapeutics has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. This focus has generated a clinical and preclinical pipeline, as well as more than 101 patents and patent applications.

Results of Operations

Three months ended April 30, 2018 compared to April 30, 2017
(in 000s)

Comparative Financial Data for the Three Months Ended April 30,

	2018			2017			Increase (Decrease)			% Change
Revenues:
Clinical laboratory services	$	18,137		$	19,584		$	(1,447	)		(7	)
Product revenues		7,415			7,312			103			1
Royalty and license fee income		78			193			(115	)		(60	)
Total revenues		25,630			27,089			(1,459	)		(5	)

Operating costs and expenses:
Cost of clinical laboratory services		10,995			11,334			(339	)		(3	)
Cost of product revenues		3,562			3,582			(20	)		(1	)
Research and development		799			766			33			4
Selling, general and administrative		11,025			10,534			491			5
Provision for uncollectible accounts receivable		396			620			(224	)		(36	)
Legal fee expense		1,651			512			1,139			222
Total operating costs and expenses		28,428			27,348			1,080			4

Operating loss		(2,798	)		(259	)		(2,539	)		**

Other income (expense):
Interest		227			115			112			97
Other		17			(74	)		91			**
Foreign currency gain (loss)		(462	)		147			(609	)		**
Loss before income taxes	$	(3,016	)	$	(71	)	$	(2,945	)		**

**	not meaningful

Consolidated Results:

The “2018 period” and the “2017 period” refer to the three months ended April 30, 2018 and 2017, respectively.

Clinical laboratory services revenues for the 2018 period were $18.1 million compared to $19.6 million in the 2017 period, a decrease of $1.5 million or 7%. Services revenue was impacted by the loss of a large medical practice that internalized approximately $1.9 million of genetic testing ordering, storm related weather in the Northeast which impacted operations by approximately $1.0 million, and by an accounts receivable reserve adjustment of approximately $0.5 million due to a commercial payer payment practice. These impacts were partially offset by an increase in core service testing volume of nearly 2% or $2.0 million from growth in genetic and esoteric testing.

The cost of clinical laboratory services during the 2018 period was $11.0 million as compared to $11.3 million in the 2017 period, a decrease of $0.3 million or 3% due to a decrease in outside reference lab testing of $1.0 million, partially offset by increases in salary expenses of $0.4 million, reagent costs of $0.2 million, and depreciation, repair and maintenance costs of $0.1 million. Gross profit margin was 39.4% in the 2018 period and 42% in the 2017 period and was impacted by the mix of tests and an increase in contractual allowances.

The cost of product revenues was $3.6 million in both the 2018 and 2017 periods. Due to a more profitable mix of products sold, the gross profit margin on products was 52% in the 2018 period and 51% in the 2017 period.

Research and development expenses were $0.8 million in both the 2018 and 2017 periods. The expense for the Life Sciences segment was $0.6 million and $0.2 million for the Therapeutics segment in both periods.

Selling, general and administrative expenses were approximately $11.0 million during the 2018 period versus $10.5 million during the 2017 period, an increase of $0.5 million or 5%. The Clinical Lab segment expense increased $0.1 million, primarily comprised of billing and collection expenses. The Life Sciences segment expense increased $0.2 million due to increases in marketing headcount. The Other segment expense increased $0.2 million from an increase in benefits expense.

The provision for uncollectible accounts receivable, primarily related to the Clinical Labs segment, was approximately $0.4 million in the 2018 period and $0.6 million in the 2017 period, a decrease of approximately $0.2 million. As a percentage of Clinical laboratory services, the provision for uncollectible accounts receivable relating to the Clinical Labs segment was 2.2% in the 2018 period and 3.3% in the 2017 period.

Legal fee expense was $1.7 million during the 2018 period compared to $0.5 million in the 2017 period, an increase of $1.1 million or 222% due to the timing of legal activity and related costs associated with on-going litigation and contract dispute where the Company is the plaintiff.

Segment Results:

Clinical Labs

Revenues from laboratory services for the 2018 period were $18.1 million compared to $19.5 million in the 2017 period. The decrease of $1.4 million or 7% is attributed to the loss of a large medical practice that internalized its genetic testing ordering, storm related weather in the Northeast, and by an accounts receivable reserve adjustment due to a commercial payer payment practice. These impacts were partially offset by an increase in core service testing volume from growth in genetic and esoteric testing. Cost of services during the 2018 period was $11.0 million as compared to $11.3 million in the 2017 period, a decrease of $0.3 million or 3% due lower costs associated with outside reference lab testing, which was partially offset by higher salary, reagent and equipment related costs. Gross profit margin was 39.4% in the 2018 period and 42% in the 2017 period and was impacted by the mix of tests and an increase in contractual allowances. Selling, general and administrative expenses increased $0.1 million for billing and collection costs. As a percentage of revenues, the provision for uncollectable accounts, primarily for self-pay patient accounts, was 2.2% for the 2018 period and 3.3% for the 2017 period. Income before taxes was $0.5 million for 2018 period as compared to $1.5 million in the 2017 period, a decrease of $1.0 million as a result of lower revenues.

Life Sciences

Product revenues for the 2018 period were $7.4 million compared to $7.3 million in the 2017 period, an increase of $0.1 million or 1%. The increase resulted from the positive impact of foreign currency translation of $0.2 million, which was partially offset by lower product order volume of $0.1 million in the United States due to lower research funding. The segment’s gross profit was $3.9 million in both the 2018 and 2017 periods. The gross profit margin on products was 52% in the 2018 period and 51% in the 2017 period and was positively impacted by slightly lower price discounting. Selling general and administrative (SG&A) expenses increased $0.2 million for marketing costs. Research and development expense in both periods was $0.6 million. Due to significant depreciation of foreign currencies versus the US dollar at the end of the 2018 period compared to the start of the 2018 period, in particular the Swiss franc, British pound and Euro, the foreign currency loss was $0.5 million compared to a gain of $0.1 million in the 2017 period, an unfavorable change of $0.6 million. The 2018 period loss before taxes was $0.1 million for as compared to income before taxes of $0.7 million for the 2017 period, a decrease of $0.8 million, the result of the foreign currency loss and increase in SG&A.

Therapeutics

The Therapeutics segment’s operating loss before income taxes was approximately $0.2 million in both the 2018 and 2017 periods.

Other

The Other segment’s loss before taxes for the 2018 period was approximately $3.2 million compared to $2.0 million for the 2017 period, an increase of $1.2 million. The 2018 period legal expense associated with on-going litigation and contract dispute increased $1.1 million. Compensation and benefits related expenses increased $0.2 million. Interest income increased $0.1 million due to the impact of a higher interest rate earned on cash and cash equivalents during the 2018 period compared to 2017.

Results of Operations

Nine months ended April 30, 2018 compared to April 30, 2017
(in 000s)

Comparative Financial Data for the Nine Months Ended April 30,

	2018			2017			Increase (Decrease)			% Change
Revenues:
Clinical laboratory services	$	58,001		$	56,979		$	1,022			2
Product revenues		21,618			21,721			(103	)		**
Royalty and license fee income		639			933			(294	)		(32	)
Total revenues		80,258			79,633			625			1

Operating costs and expenses:
Cost of clinical laboratory services		34,767			33,282			1,485			4
Cost of product revenues		10,828			10,411			417			4
Research and development		2,358			2,071			287			14
Selling, general and administrative		32,986			33,246			(260	)		(1	)
Provision for uncollectible accounts receivable		1,989			1,968			21			1
Legal fee expense		3,782			1,254			2,528			202
Total operating costs and expenses		86,710			82,232			4,478			5

Operating loss		(6,452	)		(2,599	)		(3,853	)		**

Other income (expense):
Interest		569			240			329			**
Other		86			69			17			25
Foreign currency gain (loss)		143			(308	)		451			**
Loss before income taxes	$	(5,654	)	$	(2,598	)	$	(3,056	)		(118	)

**	not meaningful

Consolidated Results:

The “2018 period” and the “2017 period” refer to the nine months ended April 30, 2018 and 2017, respectively.

Clinical laboratory services revenues for the 2018 period were $58.0 million compared to $57.0 million in the 2017 period, an increase of $1.0 million or 2%. The increase is attributed to an increase in core service testing volume from growth in genetic and esoteric testing, partially offset by the loss of a large medical practice that internalized its genetic testing ordering, storm related weather in the Northeast, and by an accounts receivable reserve adjustment due to a commercial payer payment practice.

The cost of clinical laboratory services during the 2018 period was $34.8 million as compared to $33.3 million in the 2017 period, an increase of $1.5 million or 4% due to the volume increase in clinical laboratory services, and is comprised of $1.0 million for reagents, $1.1 million in salary expenses and $0.2 million of depreciation, repair and maintenance costs, partially offset by a decrease of $0.8 million for outside reference lab testing costs due to lower molecular testing levels. Gross profit margin was 40.1% in the 2018 period and 41.6% in the 2017 period, impacted by the mix of tests.

The cost of product revenues was $10.8 million in the 2018 period and $10.4 million in the 2017 period, an increase of $0.4 million or 4% due to the sale of lower margin items. The gross profit margin on products was 50% in the 2018 period and 52% in the 2017 period, and was also negatively impacted by lower pricing due to competition.

Research and development expenses were $2.4 million versus $2.1 million in the 2018 period, an increase of $0.3 million or 14%. The expense for the Life Sciences segment was $1.7 million in both periods. The expense for the Therapeutics segment was $0.7 million in the 2018 period and $0.4 million in the 2017 period. The lower expense in the 2017 period was due to the impact of an adjustment decreasing an obligation for clinical trial activity.

Selling, general and administrative expenses were approximately $33.0 million during the 2018 period versus $33.2 million during the 2017 period, a decrease of $0.2 million or 1%. The Clinical Lab segment expense increased $0.5 million comprised of a $0.6 million increase in billing and collection expenses and a $0.1 million increase in salaries, partially offset by a decrease of $0.2 million in office materials. The Life Sciences segment expense decreased $0.1 million due to lower compensation. The Other segment expense decreased $0.6 million, comprised of a decrease in compensation related expenses of $0.5 million and a decrease of $0.1 million in office expenses.

The provision for uncollectible accounts receivable, primarily related to the Clinical Labs segment, was approximately $2.0 million in both the 2018 and 2017 periods. As a percentage of Clinical laboratory services, the provision for uncollectible accounts receivable relating to the Clinical Labs segment was 3.4% in both the 2018 and 2017 periods.

Legal fee expense was $3.8 million during the 2018 period compared to $1.3 million in the 2017 period, an increase of $2.5 million or 202% due to the timing of legal activity and related costs associated with on-going litigation and contract dispute where the Company is the plaintiff.

Segment Results:

Clinical Labs

Revenue from laboratory services for the 2018 period were $58.0 million compared to $57.0 million in the 2017 period. The increase of $1.0 million or 2% is attributed to an increase in core service testing volume from growth in genetic and esoteric testing, partially offset by the loss of a large medical practice that internalized its genetic testing ordering, storm related weather in the Northeast, and by an accounts receivable reserve adjustment due to a commercial payer payment practice. Cost of services during the 2018 period was $34.8 million as compared to $33.3 million in the 2017 period, an increase of $1.5 million or 4% due to the volume increase in clinical laboratory services, and is comprised of $1.0 million for reagents, $1.1 million in salary expenses and $0.2 million of depreciation, repair and maintenance costs, partially offset by a decrease of $0.8 million for outside reference lab testing costs relating to molecular testing levels. Gross profit margin was 40.1% in the 2018 period and 41.6% in the 2017 period and was impacted by the mix of tests and an increase in contractual allowances. As a percentage of revenues, the provision for uncollectable accounts, primarily for self-pay patient accounts, was 3.4% for both the 2018 and 2017 periods. Income before taxes was $2.7 million for 2018 period as compared to $3.8 million in the 2017 period, a decrease of $1.1 million.

Life Sciences

Product revenues for the 2018 period were $21.6 million compared to $21.7 million in the 2017 period, a decrease of $0.1 million or less than 1%. The decrease resulted from lower product order volume of $0.6 million, primarily in the United States due to lower research funding and lower pricing due to competition, which was partially offset by the positive impact of foreign currency translation of $0.5 million. The segment’s gross profit was $11.4 million in the 2018 period and $12.2 million in the 2017 period. The gross profit margin on products was 50% in the 2018 period and 52% in the 2017 period and was negatively impacted by the sale of lower margin products and price discounting. In the 2018 period, selling general and administrative expenses decreased $0.1 million compared to the 2017 period. Due to nearly offsetting impacts of the depreciation of the Swiss franc and the appreciation of the British pound and Euro versus the US dollar at the end of the 2018 period compared to the start of the 2018 period, the foreign currency gain was $0.1 million compared to a loss of $0.3 million in the 2017 period, a favorable change of $0.4 million. Income before taxes was $1.4 million for both the 2018 and 2017 periods.

Therapeutics

The Therapeutics segment’s operating loss before income taxes was approximately $0.7 million in the 2018 period and $0.4 million in the 2017 period. The lower expense during the 2017 period was due to the impact of an adjustment decreasing an obligation for clinical trial activity.

Other

The Other segment’s loss before taxes for the 2018 period was approximately $9.1 million compared to $7.4 million for the 2017 period, an increase of $1.7 million. During the 2018 period, legal fee expense associated with on-going

litigation and contract dispute increased $2.6 million. The 2018 period selling general and administrative expense declined $0.6 million compared to the 2017 period due to a $0.5 million decrease in compensation related expenses and a $0.1 million decrease in office expense. Interest income increased $0.3 million in the 2018 period due to the impact of a higher interest rate earned on cash and cash equivalents and because of interest expense incurred in the 2017 period on the then outstanding loan payable. The loan was repaid during the second quarter of 2017 period.

Liquidity and Capital Resources

At April 30, 2018, the Company had cash and cash equivalents of $62.6 million of which $0.6 million was in foreign accounts, as compared to cash and cash equivalents of $64.2 million, of which $0.5 million was in foreign accounts at July 31, 2017. It is the Company’s current intent to permanently reinvest these funds outside of the United States, and its current plans do not demonstrate a need to repatriate them to fund its United States operations. The Company had working capital of $67.8 million at April 30, 2018 compared to $71.3 million at July 31, 2017. The decrease in working capital of $3.5 million was primarily due to the period loss and net changes in operating assets and liabilities.

Net cash used in operating activities during the 2018 period was approximately $0.5 million as compared to cash used in operating activities of $1.9 million during the 2017 period, a decrease of approximately $1.4 million. The decrease is due to a net change in assets and liabilities of $4.0 million offset by an increase in net loss of $2.0 million and a $0.6 million change in non-cash adjustments.

Net cash used in investing activities in fiscal 2018 and 2017 was approximately $1.7 million and $1.4 million, respective, which consists primarily of capital expenditures.

Net cash provided by financing activities in fiscal 2018 was approximately $0.5 million as compared to cash used in financing activities of $1.8 million in fiscal 2017. The change of $2.4 million is mainly due to payments made under a credit agreement of $1.6 million in the 2017 period, an increase in proceeds from the exercise of stock options of $0.7 million, and a decrease of $0.1 million in installment loan payments in the 2018 period.

The Company believes that its current cash and cash equivalents level, and utilization of the Controlled Equity Offering program if necessary, are sufficient for its foreseeable liquidity and capital resource needs over at least the next twelve (12) months, although there can be no assurance that future events will not alter such view. Although there can be no assurances, in the event additional capital is required, the Company believes it has the ability to raise additional funds through equity offerings or other sources. Our liquidity plans are subject to a number of risks and uncertainties, including those described in the Item 1A. “Risk Factors” section of our Form 10-K for the year ended July 31, 2017, some of which are outside our control. Macroeconomic conditions could limit our ability to successfully execute our business plans and therefore adversely affect our liquidity plans.

Contractual Obligations

There have been no material changes to our Contractual Obligations as reported in our Form 10-K for the fiscal year ended July 31, 2017.

Management is not aware of any material claims, disputes or settled matters concerning third party reimbursement that would have a material effect on our financial statements, except as disclosed in Note 11 to the Consolidated Financial Statements.

Off-Balance Sheet Arrangements

The Company does not have any “off-balance sheet arrangements” as such term is defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies

The Company’s discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and judgments also affect related disclosure of contingent assets and liabilities.

On an on-going basis, we evaluate our estimates, including those related to contractual expense, allowance for uncollectible accounts, inventory, intangible assets and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily

apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Product revenues

Revenues from product sales are recognized when the products are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured.

Royalties

Royalty revenues are recorded in the period earned. Royalties received in advance of being earned are recorded as deferred revenues.

Revenues – Clinical laboratory services

Revenues from Clinical Labs are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to payers and the expected approved reimbursable settlements from such payers.

The following table represents the clinical laboratory segment’s net revenues and percentages by revenue category:

	Three months ended April 30, 2018				Three months ended April 30, 2017
Revenue category
Third-party payer	$	9,965	55	%	$	10,455	53	%
HMO’s		2,867	16			2,556	13
Medicare		2,858	16			2,832	15
Patient self-pay		2,447	13			3,741	19
Total	$	18,137	100	%	$	19,584	100	%

	Nine months ended April 30, 2018				Nine months ended April 30, 2017
Revenue category
Third-party payer	$	32,726	56	%	$	31,422	55	%
Medicare		9,073	16			8,462	15
HMO’s		8,513	15			7,478	13
Patient self-pay		7,689	13			9,617	17
Total	$	58,001	100	%	$	56,979	100	%

The Company provides services to certain patients covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs.

Contractual Adjustment

The Company’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue, based on gross billing rates, to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule we set for all third party payers, including Medicare, HMO’s and managed care. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors.

The other relevant factors that affect our contractual adjustment include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company.

Our clinical laboratory business is primarily dependent upon reimbursement from third-party payers, such as Medicare (which principally serves patients 65 and older) and insurers. We are subject to variances in reimbursement rates among different third-party payers, as well as constant changes of reimbursement rates. Changes that decrease reimbursement rates or coverage would negatively impact our revenues. The number of individuals covered under managed care contracts or other similar arrangements has grown over the past several years and may continue to grow in the future. In addition, Medicare and other government healthcare programs continue to shift to managed care. These trends will continue to reduce our revenues from these programs.

During the three months ended April 30, 2018 and 2017, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were 85.1% and 84.4%, respectively, of gross billings. During the nine months ended April 30, 2018 and 2017, the contractual adjustment percentages, determined using current and historical reimbursements statistics, were 84.7% and 83.6%, respectively. In general, the Company believes a decline in reimbursement rates or a shift to managed care or similar arrangements may be offset by the positive impact of an increase in the number of molecular tests we perform. However, there can be no assurance that we can increase the number of tests we perform or that if we do increase the number of tests we perform, that we can maintain that higher number of tests performed, or that an increase in the number of tests we perform would result in increased revenue.

The Company estimates (by using a sensitivity analysis) that each 1% point change in the contractual adjustment percentage could result in a change in clinical laboratory services revenues of approximately $3.8 million and $3.5 million for the nine months ended April 30, 2018 and 2017, respectively, and a change in the net accounts receivable of approximately $0.6 million as of April 30, 2018.

Our clinical laboratory financial billing system records gross billings using a standard fee schedule for all payers and does not record contractual adjustment by payer at the time of billing. Therefore, we are unable to quantify the effect contractual adjustments recorded during the current period have on revenue recorded in a previous period. However, we can reasonably estimate our monthly contractual adjustment to revenue on a timely basis based on our quarterly review process, which includes:

•

an analysis of industry reimbursement trends;

•

an evaluation of third-party reimbursement rates changes and changes in reimbursement arrangements with third-party payers;

•

a rolling monthly analysis of current and historical claim settlement and reimbursement experience statistics with payers; and

•

an analysis of current gross billings and receivables by payer.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.

The following is a table of the Company’s net accounts receivable by segment. The Clinical Labs segment’s net receivables are detailed by billing category and as a percent to its total net receivables. At April 30, 2018, and July 31, 2017, approximately 77% and 73%, respectively, of the Company’s net accounts receivable relates to its Clinical Labs business, which operates in the New York, New Jersey and Connecticut medical communities.

The Life Sciences segment’s accounts receivable balance includes $1.1 million or 34% and $1.1 million or 29% of foreign receivables as of April 30, 2018 and July 31, 2017.

Net accounts receivable

Billing category	As of April 30, 2018				As of July 31, 2017
Clinical Labs
Third party payers	$	5,338	49	%	$	7,256	64	%
Patient self-pay		2,690	24			1,591	14
Medicare		1,743	16			1,385	12
HMO’s		1,251	11			1,169	10
Total Clinical Labs		11,022	100	%		11,401	100	%
Total Life Sciences		3,385				3,779
Total accounts receivable	$	14,407			$	15,180

Changes in the Company’s allowance for doubtful accounts are as follows:

	Nine months ended April 30, 2018			Fiscal year ended July 31, 2017
Beginning balance	$	3,576		$	3,517
Provision for doubtful accounts		1,989			2,775
Write-offs, net		(3,658	)		(2,716	)
Ending balance	$	1,907		$	3,576

For the Clinical Labs segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and reduces the allowance in future accounting periods based on write-offs during those periods. The Company bases the estimate for the allowance on the evaluation of historical experience of accounts going to collections and the net amounts not received. Accounts going to collection include the balances, after receipt of the approved settlements from third party payers, for the insufficient diagnosis information received from the ordering physician which result in denials of payment and our estimate of the uncollected portion of receivables from self-payers, including deductibles and copayments, which are subject to credit risk and patients’ ability to pay. The Company fully reserves through its contractual allowances amounts that have not been written off because the payer’s filing date deadline has not occurred or the collection process has not been exhausted. The Company adjusts the historical collection analysis for recoveries, if any, on an on-going basis. The allowance for doubtful accounts as a percentage of total accounts receivable at April 30, 2018 and July 31, 2017 was 11.7% and 19.1%, respectively. As of April 30, 2018, the Company recorded a reclassification of approximately $1.7 million, which reduced the allowance for doubtful accounts and increased the allowance for contractual allowances; both accounts are netted against accounts receivable on the consolidated balance sheet.

The Company’s ability to collect outstanding receivables from third party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection or reimbursement issues in order to assess the impact, if any, on the allowance estimates, which involves judgment.

The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the accurate patient information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount.

Billing for laboratory services is complicated because of many factors, especially: the differences between our standard gross fee schedule for all payers and the reimbursement rates of the various payers we deal with, disparity of coverage and information requirements among the various payers, and disputes with payers as to which party is responsible for reimbursement.

The following table indicates the Clinical Labs aged gross receivables by payer group which is prior to adjustment to gross receivables for: 1) contractual adjustment, 2) fully reserved balances not yet written off, and 3) other revenue adjustments.

As of April 30, 2018	Total		%			Third Party Payers		%			Self-Pay			%			Medicare		%			HMO’s		%
1-30 days	$	24,684		45		$	15,759		43		$	1,034			17		$	4,627		52		$	3,264		91
31-60 days		7,790		14			5,424		15			1,115			18			1,037		12			214		6
61-90 days		5,365		10			3,634		10			905			15			794		9			32		1
91-120 days		3,881		7			2,437		7			787	)		13			621		7			36		1
121-150 days		2,210		4			1,392		3			470			8			346		4			2		—
Greater than 150 days		11,250		20			8,076		22			1,736	)		29			1,394		16			44		1
Totals	$	55,180		100	%	$	36,722		100	%	$	6,047			100	%	$	8,819		100	%	$	3,592		100	%

As of July 31, 2017	Total		%			Third Party Payers		%			Self-Pay			%			Medicare		%			HMO’s		%
1-30 days	$	25,357		42		$	16,683		40		$	1,082			16		$	4,022		60		$	3,570		82
31-60 days		8,732		15			5,723		14			1,183			17			1,294		19			532		12
61-90 days		5,703		10			4,208		10			927			14			529		9			39		1
91-120 days		3,749		6			2,732		6			701			10			288		4			28		1
121-150 days		3,689		6			2,772		7			672			10			228		3			17		—
Greater than 150 days		12,455		21			9,652		23			2,270			33			379		5			154		4
Totals	$	59,685		100	%	$	41,770		100	%	$	6,835			100	%	$	6,740		100	%	$	4,340		100	%

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected.

Inventory

The Company values inventory at the lower of cost (first-in, first-out) or net realizable value, which approximates market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to net realizable value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.

Goodwill and Intangible Assets

Goodwill represents the excess of the cost of an acquisition over the fair value of the net assets acquired. Intangible assets, arose primarily from acquisitions, and primarily consist of customer relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from 4 to 15 years.

The Company tests goodwill and long-lived assets annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill and long-lived assets for impairment, the Company has the option to perform a qualitative assessment to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company is not required to perform a quantitative test in assessing goodwill and long-lived assets for impairment. However, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it identifies the reporting units and compares the fair value of each of these reporting units to their respective carrying amount. If the carrying amount of the reporting unit is less than its fair value, no impairment exists. If the carrying amount of the reporting unit is higher than its fair value, the impairment charge is the amount by which the carrying amount exceeds its fair value, not to exceed the total amount of goodwill and intangibles allocated to the reporting unit.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in foreign currency exchange rates resulting from acquisitions with foreign locations (See Item 1A. Risk Factors section of the Form 10-K for the fiscal year ended July 31, 2017) that could impact our results of operations and financial position. We do not currently engage in any hedging or market risk management tools.

Foreign Currency Exchange Rate Risk

The financial reporting of our non-U.S. subsidiaries is denominated in currencies other than the U.S. dollar. Since the functional currency of our non-U.S. subsidiaries is the local currency, foreign currency translation adjustments are accumulated as a component of accumulated other comprehensive income in stockholders’ equity. Assuming a hypothetical increase of 10% in the value of the U.S. dollar versus foreign currencies at April 30, 2018, our assets and liabilities would decrease by $0.4 million and $0.1 million, respectively, and our net sales and net earnings (loss) would decrease by $0.9 million and $0.1 million, respectively, on an annual basis.

We also maintain intercompany balances and loans with subsidiaries in different local currencies. These amounts are at risk of foreign exchange losses if exchange rates fluctuate. Assuming a hypothetical increase of 10% in the value of the U.S. dollar versus foreign currencies, our pre-tax earnings (loss) would be unfavorably impacted by approximately $1.4 million on an annual basis.

Interest Rate Risk

As of April 30, 2018, we have fixed interest rate financing on transportation and equipment leases.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management conducted an evaluation (as required under Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of the Company’s “disclosure controls and procedures” (as such term is defined under the Exchange Act), under the supervision and with the participation of the principal executive officer and the principal financial officer. Based on this evaluation, the principal executive officer and the principal financial officer concluded that the Company’s disclosure controls and procedures are effective as of the end of the period covered by this report. Notwithstanding the foregoing, a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that it will detect or uncover failures within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports.

(b) Changes in Internal Controls over Financial Reporting

There was no change in the Company’s internal controls over financial reporting during the fiscal quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

There have been no other material developments with respect to previously reported legal proceedings discussed in the annual report on Form 10-K for the fiscal year ended July 31, 2017 filed with the Securities and Exchange Commission, other than as noted in Note 11 to the Consolidated Financial Statements as of April 30, 2018.

Item 1A.

Risk Factors

There have been no material changes from the risk factors disclosed in Part 1, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2017.

Item 6.

Exhibits

Exhibit No.		Exhibit
31.1		Certification of Elazar Rabbani, Ph.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Barry Weiner pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Elazar Rabbani, Ph.D. pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Barry Weiner pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101. INS*		XBRL Instance Document

101. SCH*		XBRL Taxonomy Extension Schema Document

101. CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definitions Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*XBRL (Extensible Business Reporting Language) information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ENZO BIOCHEM, INC.
	(Registrant)

Date: June 11, 2018	by:	/s/ Barry Weiner
		President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director

EX-31.1 2 c91227_ex31-1.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Elazar Rabbani, Ph.D., certify that:

I have reviewed this quarterly report on Form 10-Q of Enzo Biochem, Inc. (the “registrant”).

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 11, 2018

	By:	/s/ Elazar Rabbani, Ph.D.
		Elazar Rabbani, Ph.D.
		Chairman of the Board, Chief Executive Officer and Secretary

EX-31.2 3 c91227_ex31-2.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Barry Weiner, certify that:

I have reviewed this quarterly report on Form 10-Q of Enzo Biochem, Inc. (the “registrant”).

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 11, 2018

	By:	/s/ Barry Weiner
		Barry Weiner
		President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director

EX-32.1 4 c91227_ex32-1.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
TITLE 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-Q for the period ended April 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Elazar Rabbani, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: June 11, 2018

	By:	/s/ Elazar Rabbani, Ph.D.
		Elazar Rabbani, Ph.D.
		Chairman of the Board, Chief Executive Officer and Director

EX-32.2 5 c91227_ex32-2.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
TITLE 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-Q for the period ended April 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Barry Weiner, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: June 11, 2018

	By:	/s/ Barry Weiner
		Barry Weiner
		President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director

EX-101.INS 6 enz-20180430.xml 0000316253 2018-04-30 0000316253 2017-07-31 0000316253 enz:ClinicalLaboratoryServicesMember 2018-02-01 2018-04-30 0000316253 enz:ClinicalLaboratoryServicesMember 2017-02-01 2017-04-30 0000316253 enz:ClinicalLaboratoryServicesMember 2017-08-01 2018-04-30 0000316253 enz:ClinicalLaboratoryServicesMember 2016-08-01 2017-04-30 0000316253 us-gaap:ProductMember 2018-02-01 2018-04-30 0000316253 us-gaap:ProductMember 2017-02-01 2017-04-30 0000316253 us-gaap:ProductMember 2017-08-01 2018-04-30 0000316253 us-gaap:ProductMember 2016-08-01 2017-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember 2018-02-01 2018-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember 2017-02-01 2017-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember 2017-08-01 2018-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember 2016-08-01 2017-04-30 0000316253 2018-02-01 2018-04-30 0000316253 2017-02-01 2017-04-30 0000316253 2017-08-01 2018-04-30 0000316253 2016-08-01 2017-04-30 0000316253 us-gaap:CommonStockMember 2017-07-31 0000316253 us-gaap:AdditionalPaidInCapitalMember 2017-07-31 0000316253 us-gaap:RetainedEarningsMember 2017-07-31 0000316253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-07-31 0000316253 us-gaap:RetainedEarningsMember 2017-08-01 2018-04-30 0000316253 us-gaap:CommonStockMember 2017-08-01 2018-04-30 0000316253 us-gaap:TreasuryStockMember 2017-08-01 2018-04-30 0000316253 us-gaap:AdditionalPaidInCapitalMember 2017-08-01 2018-04-30 0000316253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-08-01 2018-04-30 0000316253 us-gaap:CommonStockMember 2018-04-30 0000316253 us-gaap:AdditionalPaidInCapitalMember 2018-04-30 0000316253 us-gaap:RetainedEarningsMember 2018-04-30 0000316253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-30 0000316253 2016-07-31 0000316253 2017-04-30 0000316253 2018-06-01 0000316253 us-gaap:SalesRevenueNetMember enz:ClinicalLabsMember 2018-02-01 2018-04-30 0000316253 us-gaap:SalesRevenueNetMember enz:ClinicalLabsMember 2017-02-01 2017-04-30 0000316253 us-gaap:SalesRevenueNetMember enz:ClinicalLabsMember 2017-08-01 2018-04-30 0000316253 us-gaap:SalesRevenueNetMember enz:ClinicalLabsMember 2016-08-01 2017-04-30 0000316253 enz:InTheMoneyStockOptionsMember enz:UnvestedRestrictedStockMember 2018-02-01 2018-04-30 0000316253 enz:InTheMoneyStockOptionsMember enz:UnvestedRestrictedStockMember 2017-08-01 2018-04-30 0000316253 enz:WeightedAverageStockOptionsMember 2017-02-01 2017-04-30 0000316253 enz:WeightedAverageStockOptionsMember 2016-08-01 2017-04-30 0000316253 enz:OutOfTheMoneyStockOptionsMember enz:OutstandingOptionsMember 2018-02-01 2018-04-30 0000316253 enz:OutOfTheMoneyStockOptionsMember enz:OutstandingOptionsMember 2017-08-01 2018-04-30 0000316253 enz:OutOfTheMoneyStockOptionsMember enz:OutstandingOptionsMember 2017-02-01 2017-04-30 0000316253 enz:OutOfTheMoneyStockOptionsMember enz:OutstandingOptionsMember 2016-08-01 2017-04-30 0000316253 us-gaap:OfficerMember 2017-08-01 2018-04-30 0000316253 2016-08-01 2017-07-31 0000316253 enz:ClinicalLabsMember 2018-04-30 0000316253 enz:ClinicalLabsMember 2017-07-31 0000316253 us-gaap:IntangibleAssetsAmortizationPeriodMember 2017-08-01 2018-04-30 0000316253 enz:LifeSciencesMember 2017-07-31 0000316253 enz:LifeSciencesMember 2017-08-01 2018-04-30 0000316253 enz:LifeSciencesMember 2018-04-30 0000316253 us-gaap:PatentsMember 2018-04-30 0000316253 us-gaap:PatentsMember 2017-07-31 0000316253 us-gaap:CustomerRelationshipsMember 2018-04-30 0000316253 us-gaap:CustomerRelationshipsMember 2017-07-31 0000316253 enz:WebsiteAndAcquiredContentMember 2018-04-30 0000316253 enz:WebsiteAndAcquiredContentMember 2017-07-31 0000316253 enz:LicensedTechnologyAndOtherMember 2018-04-30 0000316253 enz:LicensedTechnologyAndOtherMember 2017-07-31 0000316253 us-gaap:TrademarksMember 2018-04-30 0000316253 us-gaap:TrademarksMember 2017-07-31 0000316253 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2017-08-01 2018-04-30 0000316253 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2017-08-01 2018-04-30 0000316253 us-gaap:CustomerRelationshipsMember 2017-08-01 2018-04-30 0000316253 us-gaap:OtherIntangibleAssetsMember 2017-08-01 2018-04-30 0000316253 us-gaap:CapitalLeaseObligationsMember 2018-04-30 0000316253 us-gaap:CapitalLeaseObligationsMember 2017-07-31 0000316253 enz:AccruedLegalSettlementMember 2017-07-31 0000316253 enz:InstallmentLoansMember 2018-04-30 0000316253 enz:InstallmentLoansMember 2017-07-31 0000316253 2014-12-31 0000316253 enz:TwoThousandElevenPlanMember 2017-07-31 0000316253 enz:TwoThousandElevenPlanMember 2018-04-30 0000316253 us-gaap:RestrictedStockMember 2018-04-30 0000316253 us-gaap:RestrictedStockMember 2017-08-01 2018-04-30 0000316253 us-gaap:CommonStockMember 2016-08-01 2017-04-30 0000316253 enz:OptionsMember 2018-02-01 2018-04-30 0000316253 enz:OptionsMember 2017-02-01 2017-04-30 0000316253 enz:OptionsMember 2017-08-01 2018-04-30 0000316253 enz:OptionsMember 2016-08-01 2017-04-30 0000316253 enz:RestrictedStocksMember 2018-02-01 2018-04-30 0000316253 enz:RestrictedStocksMember 2017-02-01 2017-04-30 0000316253 enz:RestrictedStocksMember 2017-08-01 2018-04-30 0000316253 enz:RestrictedStocksMember 2016-08-01 2017-04-30 0000316253 enz:CostOfClinicalLaboratoryServicesMember 2017-02-01 2017-04-30 0000316253 enz:CostOfClinicalLaboratoryServicesMember 2016-08-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-02-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-02-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-08-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-08-01 2017-04-30 0000316253 2017-08-01 2017-12-31 0000316253 us-gaap:ScenarioPlanMember 2018-01-01 2018-07-31 0000316253 enz:AlternateMinimumTaxMember 2017-08-01 2018-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2018-02-01 2018-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ConsolidatedMember 2018-02-01 2018-04-30 0000316253 us-gaap:ProductMember enz:LifeSciencesMember 2018-02-01 2018-04-30 0000316253 us-gaap:ProductMember enz:ConsolidatedMember 2018-02-01 2018-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:LifeSciencesMember 2018-02-01 2018-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:ConsolidatedMember 2018-02-01 2018-04-30 0000316253 enz:ClinicalLabsMember 2018-02-01 2018-04-30 0000316253 enz:LifeSciencesMember 2018-02-01 2018-04-30 0000316253 enz:ConsolidatedMember 2018-02-01 2018-04-30 0000316253 enz:TherapeuticsMember 2018-02-01 2018-04-30 0000316253 us-gaap:AllOtherSegmentsMember 2018-02-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ClinicalLabsMember 2018-02-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:LifeSciencesMember 2018-02-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:AllOtherSegmentsMember 2018-02-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ConsolidatedMember 2018-02-01 2018-04-30 0000316253 enz:TotalMember enz:ClinicalLabsMember 2018-02-01 2018-04-30 0000316253 enz:TotalMember enz:LifeSciencesMember 2018-02-01 2018-04-30 0000316253 enz:TotalMember us-gaap:AllOtherSegmentsMember 2018-02-01 2018-04-30 0000316253 enz:TotalMember enz:ConsolidatedMember 2018-02-01 2018-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2017-02-01 2017-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ConsolidatedMember 2017-02-01 2017-04-30 0000316253 us-gaap:ProductMember enz:LifeSciencesMember 2017-02-01 2017-04-30 0000316253 us-gaap:ProductMember enz:ConsolidatedMember 2017-02-01 2017-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:LifeSciencesMember 2017-02-01 2017-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:ConsolidatedMember 2017-02-01 2017-04-30 0000316253 enz:ClinicalLabsMember 2017-02-01 2017-04-30 0000316253 enz:LifeSciencesMember 2017-02-01 2017-04-30 0000316253 enz:ConsolidatedMember 2017-02-01 2017-04-30 0000316253 enz:TherapeuticsMember 2017-02-01 2017-04-30 0000316253 us-gaap:AllOtherSegmentsMember 2017-02-01 2017-04-30 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2017-02-01 2017-04-30 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ConsolidatedMember 2017-02-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ClinicalLabsMember 2017-02-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:LifeSciencesMember 2017-02-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:AllOtherSegmentsMember 2017-02-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ConsolidatedMember 2017-02-01 2017-04-30 0000316253 enz:TotalMember enz:ClinicalLabsMember 2017-02-01 2017-04-30 0000316253 enz:TotalMember enz:LifeSciencesMember 2017-02-01 2017-04-30 0000316253 enz:TotalMember us-gaap:AllOtherSegmentsMember 2017-02-01 2017-04-30 0000316253 enz:TotalMember enz:ConsolidatedMember 2017-02-01 2017-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2017-08-01 2018-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ConsolidatedMember 2017-08-01 2018-04-30 0000316253 us-gaap:ProductMember enz:LifeSciencesMember 2017-08-01 2018-04-30 0000316253 us-gaap:ProductMember enz:ConsolidatedMember 2017-08-01 2018-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:LifeSciencesMember 2017-08-01 2018-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:ConsolidatedMember 2017-08-01 2018-04-30 0000316253 enz:ClinicalLabsMember 2017-08-01 2018-04-30 0000316253 enz:ConsolidatedMember 2017-08-01 2018-04-30 0000316253 enz:TherapeuticsMember 2017-08-01 2018-04-30 0000316253 us-gaap:AllOtherSegmentsMember 2017-08-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ClinicalLabsMember 2017-08-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:LifeSciencesMember 2017-08-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:AllOtherSegmentsMember 2017-08-01 2018-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ConsolidatedMember 2017-08-01 2018-04-30 0000316253 enz:TotalMember enz:ClinicalLabsMember 2017-08-01 2018-04-30 0000316253 enz:TotalMember enz:LifeSciencesMember 2017-08-01 2018-04-30 0000316253 enz:TotalMember us-gaap:AllOtherSegmentsMember 2017-08-01 2018-04-30 0000316253 enz:TotalMember enz:ConsolidatedMember 2017-08-01 2018-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2016-08-01 2017-04-30 0000316253 enz:ClinicalLaboratoryServicesMember enz:ConsolidatedMember 2016-08-01 2017-04-30 0000316253 us-gaap:ProductMember enz:LifeSciencesMember 2016-08-01 2017-04-30 0000316253 us-gaap:ProductMember enz:ConsolidatedMember 2016-08-01 2017-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:LifeSciencesMember 2016-08-01 2017-04-30 0000316253 enz:RoyaltyAndLicenseFeesMember enz:ConsolidatedMember 2016-08-01 2017-04-30 0000316253 enz:ClinicalLabsMember 2016-08-01 2017-04-30 0000316253 enz:LifeSciencesMember 2016-08-01 2017-04-30 0000316253 enz:ConsolidatedMember 2016-08-01 2017-04-30 0000316253 enz:TherapeuticsMember 2016-08-01 2017-04-30 0000316253 us-gaap:AllOtherSegmentsMember 2016-08-01 2017-04-30 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2016-08-01 2017-04-30 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ConsolidatedMember 2016-08-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ClinicalLabsMember 2016-08-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:LifeSciencesMember 2016-08-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:AllOtherSegmentsMember 2016-08-01 2017-04-30 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ConsolidatedMember 2016-08-01 2017-04-30 0000316253 enz:TotalMember enz:ClinicalLabsMember 2016-08-01 2017-04-30 0000316253 enz:TotalMember enz:LifeSciencesMember 2016-08-01 2017-04-30 0000316253 enz:TotalMember us-gaap:AllOtherSegmentsMember 2016-08-01 2017-04-30 0000316253 enz:TotalMember enz:ConsolidatedMember 2016-08-01 2017-04-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

62556000

64167000

14407000

15180000

7278000

7047000

2175000

2690000

86416000

89084000

7953000

7901000

7452000

2149000

2895000

1481000

333000

105451000

107665000

8250000

10350000

9795000

6720000

623000

740000

18668000

17810000

404000

983000

19072000

18793000

472000

465000

330517000

328294000

-246457000

-241900000

1847000

2013000

86379000

88872000

105451000

107665000

0.01

25000000

0.01

75000000

47161942

46506176

47161942

46506176

18137000

19584000

58001000

56979000

7415000

7312000

21618000

21721000

78000

193000

639000

933000

25630000

27089000

80258000

79633000

10995000

11334000

34767000

33282000

3562000

3582000

10828000

10411000

799000

766000

2358000

2071000

11025000

10534000

32986000

33246000

396000

620000

1989000

1968000

1651000

512000

3782000

1254000

28428000 27348000 86710000 82232000

-2798000

-259000

-6452000

-2599000

227000

115000

569000

240000

17000

-74000

86000

69000

-462000

147000

143000

-308000

-3016000

-71000

-5654000

-2598000

-1097000

-3016000

-71000

-4557000

-2598000

-0.06

0.00

-0.10

-0.06

47073

46367

46895

46310

329000

-116000

-166000

122000

-2687000

-187000

-4723000

-2476000

46506176

465000

328294000

-241900000

2013000

-4557000

340898

106911

4000

1010000

-1014000

2562

274726

3000

828000

831000

617000

37580

-106911

-232000

1014000

782000

-166000

47161942

472000

330517000

-246457000

1847000

1608000

1552000

742000

1140000

617000

601000

630000 552000 149000 -267000

1233000

3192000

257000

213000

-513000

-195000

-2126000

-459000

2846000

-1707000

1098000

4082000

704000

-475000

-1894000

1626000

1424000

-51000 6000

-1677000

-1418000

40694000

42250000

-299000

-428000

831000

159000

532000

-1825000

9000

-13000

-1611000

-5150000

67777000

62627000

ENZO BIOCHEM INC 10-Q --07-31 47165942 false 0000316253 Yes No Accelerated Filer No 2018 Q3 2018-04-30

Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of April 30, 2018, the consolidated statements of operations and comprehensive income (loss) for the three and nine month ended April 30, 2018 and 2017, the consolidated statements of cash flows for the nine months ended April 30, 2018 and 2017 and the consolidated statement of stockholders’ equity for the nine months ended April 30, 2018 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2017 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2017 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2018. Effect of New Accounting Pronouncements Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires all excess tax benefits or deficiencies to be recognized as income tax expense or benefit in the income statement. In addition, excess tax benefits should be classified along with other income tax cash flows as an operating activity in the statement of cash flows. We adopted this standard as of August 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial statements. Pronouncements Issued but Not Yet Adopted In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606. ASU 2014-09 and its amendments supersede the current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue recognition standard is to require an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled to in exchange for the goods or services it transfers control of to its customers. The standard will be effective for our fiscal year beginning August 1, 2018 and its interim periods. We are not early adopting. We expect to use the full retrospective method upon adoption by applying the standard to each prior reporting period presented. We continue to evaluate the expected impact of the standard. Based on our preliminary assessment of the standard, we expect that the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be considered an implicit price concession in determining net revenues. Accordingly, we expect to report the estimate of uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within operating costs and expenses. The adoption of this standard will also result in increased disclosure, including qualitative and quantitative disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts from customers. However, the adoption of this standard is not expected to have a material impact on our financial position or cash flows. In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for our fiscal year beginning August 1, 2019 including interim periods within that fiscal year. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We believe the adoption of this standard would materially impact our consolidated financial statements by significantly increasing our non-current assets and non-current liabilities on our consolidated balance sheets if we record the right of use assets and related lease liabilities for our existing operating leases. We will recognize expense in the consolidated statement of operations similar to current lease accounting, in the cost of sales and selling, general and administrative. In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326). This standard changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a new forward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoption of this standard is required for our annual and interim periods beginning August 1, 2020 and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial position and cash flows. In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption of this standard is required for our annual and interim periods beginning August 1, 2018 with the amendments in the update applied prospectively to an award modified on or after the adoption date. In May 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, regarding the accounting implications of the recently issued Tax Cuts and Jobs Act (the “Act”). This standard is effective immediately. The update clarifies that in a company’s financial statements that include the reporting period in which the Act was enacted, the company must first reflect the income tax effects of the Act in which the accounting under GAAP is complete. These amounts would not be provisional amounts. The company would also report provisional amounts for those specific income tax effects for which the accounting under GAAP is incomplete but a reasonable estimate can be determined. We have recorded a provisional amount which we believe is a reasonable estimate of the effects of the Act on our financial statements as of April 30, 2018. Technical corrections or other forthcoming guidance could change how we interpret provisions of the Act, which may impact our effective tax rate and could affect our deferred tax assets, tax positions and/or our tax liabilities. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 40% and 38% of the Clinical Labs segment net revenue for the three months ended April 30, 2018 and 2017 respectively, and 39% and 38% for the nine months ended April 30, 2018 and 2017, respectively.

Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires all excess tax benefits or deficiencies to be recognized as income tax expense or benefit in the income statement. In addition, excess tax benefits should be classified along with other income tax cash flows as an operating activity in the statement of cash flows. We adopted this standard as of August 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial statements.

Pronouncements Issued but Not Yet Adopted In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606. ASU 2014-09 and its amendments supersede the current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue recognition standard is to require an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled to in exchange for the goods or services it transfers control of to its customers. The standard will be effective for our fiscal year beginning August 1, 2018 and its interim periods. We are not early adopting. We expect to use the full retrospective method upon adoption by applying the standard to each prior reporting period presented. We continue to evaluate the expected impact of the standard. Based on our preliminary assessment of the standard, we expect that the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be considered an implicit price concession in determining net revenues. Accordingly, we expect to report the estimate of uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within operating costs and expenses. The adoption of this standard will also result in increased disclosure, including qualitative and quantitative disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts from customers. However, the adoption of this standard is not expected to have a material impact on our financial position or cash flows. In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for our fiscal year beginning August 1, 2019 including interim periods within that fiscal year. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We believe the adoption of this standard would materially impact our consolidated financial statements by significantly increasing our non-current assets and non-current liabilities on our consolidated balance sheets if we record the right of use assets and related lease liabilities for our existing operating leases. We will recognize expense in the consolidated statement of operations similar to current lease accounting, in the cost of sales and selling, general and administrative. In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326). This standard changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a new forward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoption of this standard is required for our annual and interim periods beginning August 1, 2020 and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial position and cash flows. In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption of this standard is required for our annual and interim periods beginning August 1, 2018 with the amendments in the update applied prospectively to an award modified on or after the adoption date. In May 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, regarding the accounting implications of the recently issued Tax Cuts and Jobs Act (the “Act”). This standard is effective immediately. The update clarifies that in a company’s financial statements that include the reporting period in which the Act was enacted, the company must first reflect the income tax effects of the Act in which the accounting under GAAP is complete. These amounts would not be provisional amounts. The company would also report provisional amounts for those specific income tax effects for which the accounting under GAAP is incomplete but a reasonable estimate can be determined. We have recorded a provisional amount which we believe is a reasonable estimate of the effects of the Act on our financial statements as of April 30, 2018. Technical corrections or other forthcoming guidance could change how we interpret provisions of the Act, which may impact our effective tax rate and could affect our deferred tax assets, tax positions and/or our tax liabilities.

Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 40% and 38% of the Clinical Labs segment net revenue for the three months ended April 30, 2018 and 2017 respectively, and 39% and 38% for the nine months ended April 30, 2018 and 2017, respectively.

0.40

0.38

0.39

0.38

Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three and nine months ended April 30, 2018 and 2017 diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three and nine months ended April 30, 2018, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 431,000 and 694,000, respectively, because their effect would be antidilutive. For the three and nine months ended April 30, 2017, approximately 987,000 and 865,000 weighted average stock options were excluded from the calculation of diluted weighted average shares outstanding because their effect would be antidilutive. For the three and nine months ended April 30, 2018, the effect of approximately 581,000 and 194,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and nine months ended April 30, 2017, the effect of approximately zero and 165,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

431000

694000

987000

865000

581000

194000

165000

Note 3 - Supplemental disclosure for statement of cash flows For the nine months ended April 30, 2018 and 2017, income taxes paid by the Company were $65 and $1,021, respectively.  For the nine months ended April 30, 2018 and 2017, interest paid by the Company was $61 and $99, respectively. For the nine months ended April 30, 2018 and 2017, the Company financed $0 and $69 respectively, in machinery and transportation equipment under installment loans.  During the nine months ended April 30, 2018 certain officers of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares, as treasury stock. During the nine months ended April 30, 2018, the Company contributed its treasury stock and issued common stock in connection with its share-based 401(k) employer match in the amount of $782. For the 2017 period, the Company issue shares of common stock in the amount of $724.

65000

1021000

61000

99000

0 69000

340898

106911

1014000

724000

Note 4 – Inventories Inventories consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 70%; text-align: left">Raw materials</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">817</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">852</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,065</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,905</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Finished products</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">4,396</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">4,290</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">7,278</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">7,047</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

Inventories consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 70%; text-align: left">Raw materials</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">817</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">852</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,065</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,905</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Finished products</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">4,396</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">4,290</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">7,278</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">7,047</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

817000

852000

2065000

1905000

4396000

4290000

Note 5 – Goodwill and intangible assets At April 30, 2018 and July 31, 2017, the Company’s carrying amount of goodwill, related to the Clinical Labs segment, is $7,452. The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 98%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td colspan="2" style="border-bottom: Black 1px solid; text-align: center">Gross</td><td style="text-align: center; padding-bottom: 1px"> </td><td style="text-align: center; padding-bottom: 1px"> </td> <td colspan="2" style="border-bottom: Black 1px solid; text-align: center">Accumulated Amortization</td><td style="text-align: center; padding-bottom: 1px"> </td><td style="text-align: center; padding-bottom: 1px"> </td> <td colspan="2" style="border-bottom: Black 1px solid; text-align: center">Net</td><td style="text-align: left; padding-bottom: 1px"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 56%">July 31, 2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">27,436</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(24,541</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,895</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(742</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(742</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Foreign currency translation</td><td style="padding-bottom: 1px"> </td> <td style="text-align: left; border-bottom: Black 1px solid"> </td><td style="text-align: right; border-bottom: Black 1px solid">2</td><td style="text-align: left; padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="text-align: left; border-bottom: Black 1px solid"> </td><td style="text-align: right; border-bottom: Black 1px solid">(6</td><td style="text-align: left; padding-bottom: 1px">)</td><td style="padding-bottom: 1px"> </td> <td style="text-align: left; border-bottom: Black 1px solid"> </td><td style="text-align: right; border-bottom: Black 1px solid">(4</td><td style="text-align: left; padding-bottom: 1px">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">April 30, 2018</td><td style="padding-bottom: 3px"> </td> <td style="text-align: left; border-bottom: Black 3px double">$</td><td style="text-align: right; border-bottom: Black 3px double">27,438</td><td style="text-align: left; padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="text-align: left; border-bottom: Black 3px double">$</td><td style="text-align: right; border-bottom: Black 3px double">(25,289</td><td style="text-align: left; padding-bottom: 3px">)</td><td style="padding-bottom: 3px"> </td> <td style="text-align: left; border-bottom: Black 3px double">$</td><td style="text-align: right; border-bottom: Black 3px double">2,149</td><td style="text-align: left; padding-bottom: 3px"> </td></tr> </table> Intangible assets, all finite lived, consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px; text-align: center"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; text-align: center"> </td><td style="padding-bottom: 1px; text-align: center"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Gross</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Accumulated Amortization</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Net</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Gross</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Accumulated Amortization</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Net</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 41%; text-indent: -8.65pt; padding-left: 8.65pt">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,027</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(10,971</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">56</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,027</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(10,951</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,799</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,083</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,798</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Website and acquired content</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,010</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,011</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,011</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Licensed technology and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(492</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(463</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px">Trademarks</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,017</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(3,017</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,033</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(3,033</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">27,438</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(25,289</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,149</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">27,436</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(24,541</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,895</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> At April 30, 2018, information with respect to intangibles assets acquired is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1px"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Useful life assigned</td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted average remaining useful life</td> <td style="padding-bottom: 1px"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 65%; text-align: left">Customer relationships </td><td style="width: 2%"> </td> <td style="width: 10%; text-align: center">8 -15 years</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center">2.5 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Other intangibles </td><td> </td> <td style="text-align: center">10 years</td><td> </td> <td style="text-align: center">1.5 years</td> <td> </td></tr> </table> At April 30, 2018, the weighted average remaining useful life of intangible assets is approximately two years.

7452000

P2Y

The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 98%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td colspan="2" style="border-bottom: Black 1px solid; text-align: center">Gross</td><td style="text-align: center; padding-bottom: 1px"> </td><td style="text-align: center; padding-bottom: 1px"> </td> <td colspan="2" style="border-bottom: Black 1px solid; text-align: center">Accumulated Amortization</td><td style="text-align: center; padding-bottom: 1px"> </td><td style="text-align: center; padding-bottom: 1px"> </td> <td colspan="2" style="border-bottom: Black 1px solid; text-align: center">Net</td><td style="text-align: left; padding-bottom: 1px"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 56%">July 31, 2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">27,436</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(24,541</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,895</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(742</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(742</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Foreign currency translation</td><td style="padding-bottom: 1px"> </td> <td style="text-align: left; border-bottom: Black 1px solid"> </td><td style="text-align: right; border-bottom: Black 1px solid">2</td><td style="text-align: left; padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="text-align: left; border-bottom: Black 1px solid"> </td><td style="text-align: right; border-bottom: Black 1px solid">(6</td><td style="text-align: left; padding-bottom: 1px">)</td><td style="padding-bottom: 1px"> </td> <td style="text-align: left; border-bottom: Black 1px solid"> </td><td style="text-align: right; border-bottom: Black 1px solid">(4</td><td style="text-align: left; padding-bottom: 1px">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">April 30, 2018</td><td style="padding-bottom: 3px"> </td> <td style="text-align: left; border-bottom: Black 3px double">$</td><td style="text-align: right; border-bottom: Black 3px double">27,438</td><td style="text-align: left; padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="text-align: left; border-bottom: Black 3px double">$</td><td style="text-align: right; border-bottom: Black 3px double">(25,289</td><td style="text-align: left; padding-bottom: 3px">)</td><td style="padding-bottom: 3px"> </td> <td style="text-align: left; border-bottom: Black 3px double">$</td><td style="text-align: right; border-bottom: Black 3px double">2,149</td><td style="text-align: left; padding-bottom: 3px"> </td></tr> </table>

27436000

-24541000

2895000

-742000

2000 -6000

-4000

27438000

-25289000

2149000

Intangible assets, all finite lived, consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px; text-align: center"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; text-align: center"> </td><td style="padding-bottom: 1px; text-align: center"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Gross</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Accumulated Amortization</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Net</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Gross</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Accumulated Amortization</td><td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">Net</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 41%; text-indent: -8.65pt; padding-left: 8.65pt">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,027</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(10,971</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">56</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,027</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(10,951</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,799</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,083</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,798</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Website and acquired content</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,010</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,011</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,011</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Licensed technology and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(492</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(463</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px">Trademarks</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,017</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(3,017</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,033</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(3,033</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">27,438</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(25,289</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,149</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">27,436</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(24,541</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,895</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

11027000

10971000

56000

11027000

10951000

76000

11892000

9799000

2093000

11881000

9083000

2798000

1010000

1011000

492000

484000

463000

21000

3017000

3033000

27438000

25289000

2149000

27436000

24541000

2895000

At April 30, 2018, information with respect to intangibles assets acquired is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1px"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Useful life assigned</td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted average remaining useful life</td> <td style="padding-bottom: 1px"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 65%; text-align: left">Customer relationships </td><td style="width: 2%"> </td> <td style="width: 10%; text-align: center">8 -15 years</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center">2.5 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Other intangibles </td><td> </td> <td style="text-align: center">10 years</td><td> </td> <td style="text-align: center">1.5 years</td> <td> </td></tr> </table>

P8Y

P15Y

P2Y6M

P10Y

P1Y6M

Note 6 – Accrued Liabilities Accrued liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 70%; text-align: left">Payroll, benefits, and commissions</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,343</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,092</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Legal fee expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">599</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">143</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px">Other</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">2,287</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,444</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">9,795</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">6,720</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> At April 30, 2018, other accrued liabilities primarily include $400 for a legal settlement.

400000

Accrued liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 70%; text-align: left">Payroll, benefits, and commissions</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,343</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,092</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Legal fee expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">599</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">143</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px">Other</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">2,287</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,444</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">9,795</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">6,720</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

4343000

4092000

2401000 599000

764000

442000

143000

2287000

1444000

Note 7 – Other Liabilities Other liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 70%; text-align: left">Capital lease obligations, net of short term</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">397</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">551</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued legal settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">410</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Installment loans, net of short term</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">22</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">404</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">983</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> </table> As of April 30, 2018, future minimum payments under the capital leases, net of interest of $75 aggregates $570 including a short term debt portion of $173 included in other current liabilities. Future minimum payments under the installment loans aggregate $44, including a short term portion of $37 included in other current liabilities.

75000

570000

173000

44000

37000

Other liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">April 30, 2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 70%; text-align: left">Capital lease obligations, net of short term</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">397</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">551</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued legal settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">410</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Installment loans, net of short term</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">22</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">404</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">983</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> </table>

397000

551000

410000

7000

22000

404000

983000

Note 8 – Stockholders’ Equity Controlled Equity Offering The Company has a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The initial agreement contemplated the sale of shares of the Company’s common stock having an aggregate offering price of up to $20.0 million. In December 2014, the Sales Agreement was amended in order for the Company to offer and sell additional shares of Common Stock having an aggregate offering price of $20.0 million. On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017. During the nine months ended April 30, 2018 and during fiscal 2017, the Company did not sell any shares of Common Stock under the Sales Agreement. Treasury stock During the nine months ended April 30, 2018, certain officers of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares, as treasury stock. All of the treasury shares were used in the share-based 401(k) employer match made during the nine months ended April 30, 2018. Share-based compensation The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Plan”). The 2011 Incentive Plan, which is the only plan from which awards may be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards. At the 2017 annual meeting, shareholders approved the amendment and restatement of the 2011 Plan, including an increase in the number of shares of common stock authorized for grant under the 2011 Plan, from 3 million shares to 5 million shares. The amounts of share-based compensation expense recognized in the periods presented are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended April 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 42%; text-align: left">Stock options </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">202</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">204</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">609</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">586</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Restricted stock </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">2</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">5</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">8</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">15</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">204</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">209</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">617</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">601</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended April 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 42%; text-align: left">Cost of clinical laboratory services </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">204</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">207</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">617</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">596</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">204</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">209</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">617</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">601</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> No excess tax benefits were recognized during the nine month periods ended April 30, 2018 and 2017. Stock Option Plans The following table summarizes stock option activity during the nine month period ended April 30, 2018: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Options</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Remaining Contractual Term</td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Aggregate Intrinsic Value (000s)</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 44%">Outstanding at July 31, 2017 </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,130,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4.26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 12%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Awarded </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.36</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Exercised </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(615,624</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2.99</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,896</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Cancelled or expired </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(29,334</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left">$</td><td style="padding-bottom: 1px; text-align: right">5.94</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px; text-align: right"> </td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Outstanding at end of period </td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left; border-bottom: Black 3px double"> </td><td style="border-bottom: Black 3px double; text-align: right">1,603,617</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td><td style="padding-bottom: 3px; text-align: right">5.02</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="text-align: right; padding-bottom: 3px">2.6 years</td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td><td style="padding-bottom: 3px; text-align: right">4,344</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercisable at end of period </td><td> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td><td style="border-bottom: Black 3px double; text-align: right">1,168,489</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">1.2 years</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,261</td><td style="text-align: left"> </td></tr> </table> As of April 30, 2018, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.9 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is fourteen months. The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options. Restricted Stock Awards A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Awards</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Award Price</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 62%">Outstanding at July 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">7,436</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Awarded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,562</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(5.51</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1px">Forfeited</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(386</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px; text-align: right">(5.62</td><td style="padding-bottom: 1px; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Unvested at end of period</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td><td style="border-bottom: Black 3px double; text-align: right">4,488</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td><td style="padding-bottom: 3px; text-align: right">2.97</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2018, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately twenty-two months. The fair value of the awards that vested during the nine months ended April 30, 2018 and 2017 was $22 and $19, respectively. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 2,266,800 shares as of April 30, 2018. During the nine months ended April 30, 2018, the Company contributed $782 to match its employees’ 401(k) contributions with 106,911 shares of treasury stock and by issuing 37,580 shares of its common stock, representing the fair value of the shares at the match date, and adjusted treasury stock, common stock and additional paid in capital by the same amount. During the nine months ended April 30, 2017, the Company contributed $724 to match its employees’ 401(k) contributions by issuing 91,541 shares of its common stock, representing the fair value of the shares at the match date, and adjusted common stock and additional paid in capital by the same amount.

0.030 20000000 20000000 19150000 150000000

3000000

5000000

900000

P14M

100000

P22M

22000

19000

2266800

724000

91541

The amounts of share-based compensation expense recognized in the periods presented are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended April 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 42%; text-align: left">Stock options </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">202</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">204</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">609</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">586</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Restricted stock </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">2</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">5</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">8</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">15</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">204</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">209</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">617</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">601</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

202000

204000

609000

586000

2000

5000

8000

15000

204000

209000

617000

601000

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended April 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2018</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1px solid">2017</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 42%; text-align: left">Cost of clinical laboratory services </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">204</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">207</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">617</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">596</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">204</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">209</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">617</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">601</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

2000

5000

204000

207000

617000

596000

204000

209000

617000

601000

The following table summarizes stock option activity during the nine month period ended April 30, 2018: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Options</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Remaining Contractual Term</td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Aggregate Intrinsic Value (000s)</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 44%">Outstanding at July 31, 2017 </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,130,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4.26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 12%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Awarded </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.36</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Exercised </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(615,624</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2.99</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,896</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Cancelled or expired </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(29,334</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left">$</td><td style="padding-bottom: 1px; text-align: right">5.94</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px; text-align: right"> </td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Outstanding at end of period </td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left; border-bottom: Black 3px double"> </td><td style="border-bottom: Black 3px double; text-align: right">1,603,617</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td><td style="padding-bottom: 3px; text-align: right">5.02</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="text-align: right; padding-bottom: 3px">2.6 years</td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td><td style="padding-bottom: 3px; text-align: right">4,344</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercisable at end of period </td><td> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td><td style="border-bottom: Black 3px double; text-align: right">1,168,489</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">1.2 years</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,261</td><td style="text-align: left"> </td></tr> </table>

2130995

4.26

117580

8.36

615624

2.99

5896000

29334

5.94

1603617

5.02

P2Y219D

4344000

1168489

4.25

P1Y73D

2261000

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Awards</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Award Price</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 62%">Outstanding at July 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">7,436</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Awarded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,562</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(5.51</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1px">Forfeited</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(386</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px; text-align: right">(5.62</td><td style="padding-bottom: 1px; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Unvested at end of period</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td><td style="border-bottom: Black 3px double; text-align: right">4,488</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td><td style="padding-bottom: 3px; text-align: right">2.97</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

7436

4.45

2562

-5.51

386

-5.62

4488

2.97

Note 9 – Income taxes On December 22, 2017, legislation commonly known as the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. The Company calculated its best estimate of the impact of the Act in accordance with its understanding of the Act and guidance available as of the date of this filing and recorded $1.1 million as an income tax benefit in the nine months ended April 30, 2018, the period in which the legislation was enacted, related to a credit for alternative minimum taxes (AMT) paid in prior periods. A provisional amount related to the remeasurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was fully offset by an equivalent adjustment to the deferred tax valuation allowance. No provisional amount related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings was deemed necessary. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In accordance with SAB 118, the Company has determined that the $1.1 million income tax benefit, which relates to the AMT credit, is a provisional amount and a reasonable estimate at April 30, 2018. The Company’s effective tax rate benefit for the three and nine months ended April 30, 2018 was zero and 24.1%, respectfully and was based on the refundable federal AMT credit. There was no tax provision or benefit for the 2017 periods. The Company’s effective tax rate for all periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.

0.35

0.21

1100000

0.00

0.241

Note 10 – Segment reporting The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. When recognized, legal settlements, net represents activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the patents or products covered by the settlements. Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2017. The following financial information represents the operating results of the reportable segments of the Company: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Three months ended April 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,137</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,415</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">78</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">78</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">18,137</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,493</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">25,630</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,995</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,995</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,562</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">799</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,799</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,025</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">396</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">25</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">19</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,607</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,651</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">17,672</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,127</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">223</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,406</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">28,428</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">366</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(223</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,406</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,798</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange loss</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(462</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(462</td><td style="padding-bottom: 1px; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">458</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(82</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(223</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(3,169</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(3,016</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">437</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">358</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">20</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">815</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">26</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">17</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">161</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">204</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">26</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">17</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">161</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">204</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">465</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">96</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">561</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Three months ended April 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,584</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,584</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,312</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">193</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">193</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">19,584</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,505</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">27,089</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,582</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,745</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,671</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,534</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">4</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">42</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">466</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">512</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">18,106</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">6,891</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">214</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">2,137</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">27,348</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(214</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,137</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(259</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(98</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(74</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange gain</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">147</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">147</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,457</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">675</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(214</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(1,989</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(71</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">390</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">423</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">37</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">850</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">38</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">23</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">146</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">207</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">40</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">23</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">146</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">209</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">483</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">252</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">735</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Nine months ended April 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">58,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">58,001</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">21,618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,618</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">639</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">639</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">58,001</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">22,257</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">80,258</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,767</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,767</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,828</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,828</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,690</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,045</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,986</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,989</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">46</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">47</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,689</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,782</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">55,267</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">21,041</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">668</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">9,734</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">86,710</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(668</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,734</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,452</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(70</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">569</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange gain</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">143</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">143</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,696</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,404</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(668</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(9,086</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(5,654</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,254</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,039</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">57</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,350</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">86</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">61</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">470</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">617</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">86</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">61</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">470</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">617</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,459</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">167</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,626</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Nine months ended April 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">56,979</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">56,979</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">21,721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,721</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">933</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">933</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">56,979</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">22,654</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">79,633</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,282</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,282</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,411</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,071</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,596</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,246</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,910</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,968</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">105</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">70</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,079</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,254</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">53,264</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">20,830</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">376</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,762</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">82,232</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,715</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(376</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,657</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,599</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(85</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(98</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange loss</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(308</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(308</td><td style="padding-bottom: 1px; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">3,756</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,452</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(376</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(7,430</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(2,598</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,185</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,432</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">75</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,692</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">74</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">49</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">473</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">596</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">79</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">49</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">473</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">601</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,070</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">354</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,424</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

The following financial information represents the operating results of the reportable segments of the Company: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Three months ended April 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,137</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,415</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">78</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">78</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">18,137</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,493</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">25,630</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,995</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,995</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,562</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">799</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,799</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,025</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">396</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">25</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">19</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,607</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,651</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">17,672</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,127</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">223</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,406</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">28,428</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">366</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(223</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,406</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,798</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange loss</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(462</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(462</td><td style="padding-bottom: 1px; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">458</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(82</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(223</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(3,169</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(3,016</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">437</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">358</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">20</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">815</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">26</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">17</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">161</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">204</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">26</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">17</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">161</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">204</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">465</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">96</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">561</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Three months ended April 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,584</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">19,584</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,312</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">193</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">193</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">19,584</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,505</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">27,089</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,582</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,745</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,671</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,534</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">4</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">42</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">466</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">512</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">18,106</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">6,891</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">214</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">2,137</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">27,348</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(214</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,137</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(259</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(98</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(74</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange gain</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">147</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">147</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,457</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">675</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(214</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(1,989</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(71</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">390</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">423</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">37</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">850</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">38</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">23</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">146</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">207</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">40</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">23</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">146</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">209</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">483</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">252</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">735</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Nine months ended April 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">58,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">58,001</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">21,618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,618</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">639</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">639</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">58,001</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">22,257</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">80,258</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,767</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,767</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,828</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,828</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,690</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,045</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,986</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,989</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">46</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">47</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,689</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">3,782</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">55,267</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">21,041</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">668</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">9,734</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">86,710</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(668</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,734</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,452</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(70</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">569</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange gain</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">143</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">143</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,696</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,404</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(668</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(9,086</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(5,654</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,254</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,039</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">57</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,350</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">86</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">61</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">470</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">617</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">86</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">61</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">470</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">617</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,459</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">167</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,626</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td colspan="21">Nine months ended April 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Clinical Labs</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Life Sciences</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Therapeutics</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Other</td><td style="padding-bottom: 1px; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Consolidated</td><td style="padding-bottom: 1px; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline">Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 40%; text-align: left">Clinical laboratory services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">56,979</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">56,979</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">21,721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,721</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Royalty and license fee income</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">933</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">933</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">56,979</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">22,654</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">79,633</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-decoration: underline; text-align: left">Operating costs and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,282</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,282</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of product revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,411</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,071</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,596</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,246</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left">Provision for uncollectible accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,910</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,968</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Legal fee expense</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">105</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">70</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,079</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">1,254</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Total operating costs and expenses</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">53,264</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">20,830</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">376</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">7,762</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">82,232</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,715</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(376</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,657</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,599</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Other income (expense):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(85</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(98</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1px">Foreign exchange loss</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(308</td><td style="padding-bottom: 1px; text-align: left">)</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">(308</td><td style="padding-bottom: 1px; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Income (loss) before income taxes</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">3,756</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,452</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(376</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(7,430</td><td style="padding-bottom: 3px; text-align: left">)</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">(2,598</td><td style="padding-bottom: 3px; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 3px">Depreciation and amortization included above</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,185</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,432</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">75</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">2,692</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left">Share-based compensation included in above:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cost of clinical laboratory services</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px">Selling, general and administrative</td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">74</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">49</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">—</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td><td style="border-bottom: Black 1px solid; text-align: right">473</td><td style="padding-bottom: 1px; text-align: left"> </td><td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td><td style="border-bottom: Black 1px solid; text-align: right">596</td><td style="padding-bottom: 1px; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 3px">Total</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">79</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">49</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">473</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">601</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px">Capital expenditures</td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,070</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">354</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">—</td><td style="padding-bottom: 3px; text-align: left"> </td><td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td><td style="border-bottom: Black 3px double; text-align: right">1,424</td><td style="padding-bottom: 3px; text-align: left"> </td></tr> </table>

18137000

7415000

78000

18137000

7493000

25630000

10995000

3562000

576000

223000

799000

6252000

2974000

1799000

11025000

400000

-4000

396000

25000

19000

1607000

1651000

17672000

7127000

223000

3406000

28428000

465000

366000

-223000

-3406000

-2798000

-22000

12000

237000

227000

15000

2000

17000

-462000

458000

-82000

-223000

-3169000

-3016000

437000

358000

20000

815000

26000

17000

161000

204000

26000

17000

161000

204000

465000

96000

561000

19584000

7312000

193000

19584000

7505000

27089000

11334000

3582000

552000

214000

766000

6118000

2745000

1671000

10534000

650000

-30000

620000

4000

42000

466000

512000

18106000

6891000

214000

2137000

27348000

1478000

614000

-214000

-2137000

-259000

-28000

12000

131000

115000

7000

-98000

17000

-74000

147000

1457000

675000

-214000

-1989000

-71000

390000

423000

37000

850000

2000

38000

23000

146000

207000

40000

23000

146000

209000

483000

252000

735000

58001000

21618000

639000

58001000

22257000

80258000

34767000

10828000

1690000

668000

2358000

18454000

8487000

6045000

32986000

2000000

-11000

1989000

46000

47000

3689000

3782000

55267000

21041000

668000

9734000

86710000

2734000

1216000

-668000

-9734000

-6452000

-70000

35000

604000

569000

32000

10000

44000

86000

143000

2696000

1404000

-668000

-9086000

-5654000

1254000

1039000

57000

2350000

86000

61000

470000

617000

86000

61000

470000

617000

1459000

167000

1626000

56979000

21721000

933000

56979000

22654000

79633000

33282000

10411000

1695000

376000

2071000

17967000

8596000

6683000

33246000

1910000

58000

1968000

105000

70000

1079000

1254000

53264000

20830000

376000

7762000

82232000

3715000

1824000

-376000

-7657000

-2599000

-85000

34000

291000

240000

126000

-98000

41000

69000

-308000

3756000

1452000

-376000

-7430000

-2598000

1185000

1432000

75000

2692000

5000

74000

49000

473000

596000

79000

49000

473000

601000

1070000

354000

1424000

Note 11 – Contingencies The Company is engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. In December 2013, the Court granted in part and denied in part Roche’s summary judgment motion. In October 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by the end of January 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On October 2, 2017, the Court issued its claim construction ruling. On May 11, 2018, the Court issued a revised scheduling order which required the completion of expert discovery by July 13, 2018 and scheduled a conference on August 17, 2018 that will function as a pre-trial conference or a pre-motion conference. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them. There are seven pending cases originally brought by the Company in the United States District Court for the District of Delaware (“the Court”) alleging patent infringement against various companies.  On June 28, 2017, the Court issued an opinion in the Gen-Probe case, granting Gen-Probe’s motion for summary judgment that the asserted claims of the ’180 patent are invalid for nonenablement. The Court entered final judgment of invalidity of the asserted claims of the ‘180 patent on July 19, 2017 in the Gen-Probe and Hologic cases.  The Court entered partial final judgment of invalidity of the asserted claims of the ‘180 patent and stayed the remainder of the cases in the Becton Dickinson and Roche cases on July 31, 2017 and August 2, 2017, respectively.  The Company filed notices of appeal in each of the Gen-Probe, Hologic, Becton Dickinson, and Roche cases, which were docketed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”).  In the Abbott case, the parties agreed that the Court’s summary judgment ruling in the Gen-Probe case invalidated all of the ’180 patent claims asserted against the Abbott Defendants.  On August 15, 2017, the Court granted Abbott’s motion for summary judgment that the asserted claims of the ’405 patent are invalid for nonenablement.  On September 1, 2017, the Court entered final judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents for nonenablement in the Abbott case.  Enzo subsequently filed a notice of appeal in the Abbott case on September 14, 2017.  The Federal Circuit docketed the appeal on September 15, 2017.  The Federal Circuit consolidated the appeals from the Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche litigations (“Consolidated Appeals”).  We disagree with the Court’s invalidity decisions regarding the ‘180 and ‘405 patents in the pending cases as set forth in our opening brief in the Consolidated Appeals pending in the Federal Circuit filed on November 28, 2017.  In the Consolidated Appeals, we have asked the Federal Circuit to reverse the Court’s grants of final and summary judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents and to remand the cases against Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche to the Court.  Briefing is now complete in the Consolidated Appeals.  The parties await the Federal Circuit’s scheduling of an oral argument date for the Consolidated Appeals.  In the other two cases involving Hologic, one of the cases is stayed (Hologic II), while the other case (Hologic III) that involves the ‘581 patent is proceeding under the Court’s scheduling order with fact and expert discovery deadlines through September 2018, a summary judgment hearing date in April 2019, and a trial date in September 2019.  In Hologic III, the Court granted Enzo’s motion to amend its complaint to add two new defendants, Grifols Diagnostic Solutions, Inc. and Grifols, S.A, to that case.  Grifols, S.A. has moved to dismiss for lack of personal jurisdiction; briefing on that motion is complete but the Court has not set a date for oral argument.  The parties have completed claim construction briefing, and a claim construction hearing is scheduled for July 2, 2018.  Regarding Hologic’s petition requesting institution of an inter partes review proceeding regarding the U.S Patent No. 6,221,581 (“the ‘581 patent”) filed with the United States Patent and Trademark Office (“PTO”), the Patent Trial and Appeals Board (“the Board”) denied institution of Hologic’s petition on April 18, 2018.  On May 18, 2018, Hologic filed with the Board a request for rehearing of the order denying institution of inter partes review of the ‘581 patent.  Enzo has requested permission to file a brief in response to Hologic’s request for rehearing. There can be no assurance that the Company will be successful in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.

7 2

EX-101.SCH 7 enz-20180430.xsd 001 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Net income (loss) per share link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Supplemental disclosure for statement of cash flows link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Goodwill and intangible assets link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Other Liabilities link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Income taxes link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Segment reporting link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Contingencies link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Goodwill and intangible assets (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Other Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Segment reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Basis of Presentation (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Supplemental disclosure for statement of cash flows (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Inventories (Details) - Schedule of inventory, current link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Goodwill and intangible assets (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Goodwill and intangible assets (Details) - Schedule of intangible assets link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Accrued Liabilities (Details) - Accrued liabilities link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Other Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Other Liabilities (Details) - Schedule of other liabilities link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option plans link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Stockholders' Equity (Details) - Schedule of restricted stock awards link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Income taxes (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Segment reporting (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Segment reporting (Details) - Schedule of segment reporting information, by segment link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 enz-20180430_cal.xml EX-101.DEF 9 enz-20180430_def.xml EX-101.LAB 10 enz-20180430_lab.xml Statement of Financial Position [Abstract] Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Accounts receivable, net of allowances Inventories Prepaid expenses and other Total current assets Property, plant and equipment, net Goodwill Intangible assets, net Other assets Total assets Accounts payable – trade Accrued liabilities Other current liabilities Total current liabilities Other liabilities Total liabilities Commitments and contingencies Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding Preferred Stock, par value (in Dollars per share) Preferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 47,161,942 at April 30, 2018 and 46,506,176 at July 31, 2017 Common Stock, par value (in Dollars per share) Common Stock, Par or Stated Value Per Share (in Dollars per share) Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Income Statement [Abstract] Product and Service [Axis] Clinical Laboratory Services [Member] Revenues Revenues Product [Member] Royalty and License Fees [Member] Cost of Revenues Cost of Revenues Research and development Selling, general and administrative Selling, general and administrative Provision for uncollectible accounts receivable Legal fee expense Total operating costs and expenses Operating loss Operating income (loss) Interest Other Other Foreign exchange gain (loss) Foreign exchange gain (loss) Loss before income taxes Benefit for income taxes Income Tax Expense (Benefit) (in Dollars) Net loss Net loss Net loss for the period ended April 30, 2018 Net loss Basic and diluted (in Dollars per share) Basic and diluted (in Shares) Statement of Comprehensive Income [Abstract] Foreign currency translation adjustments Comprehensive loss Statement of Stockholders' Equity [Abstract] Balance, Shares (in Shares) Balance, Shares (in Shares) Cashless options exercise Treasury Stock, Value, Acquired, Cost Method Cashless options exercise, Shares (in Shares) Treasury Stock, Shares, Acquired (in Shares) Vesting of restricted stock, Shares (in Shares) Exercise of stock options Exercise of stock options, Shares (in Shares) Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) Share-based compensation charges Issuance of common stock and treasury stock for employee 401(k) plan match Stock Issued During Period, Value, Employee Benefit Plan Issuance of common stock and treasury stock for employee 401(k) plan match, Shares (in Shares) Stock Issued During Period, Shares, Employee Benefit Plan (in Shares) Equity Components [Axis] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Statement of Cash Flows [Abstract] Depreciation and amortization of property, plant and equipment Amortization of intangible assets Amortization expense Amortization expense Share-based compensation charges Accrual for share-based 401(k) employer match expense Foreign exchange (gain) loss Accounts receivable Inventories Prepaid expenses and other Accounts payable – trade Accrued liabilities, other current liabilities and other liabilities Other assets Total adjustments Net cash used in operating activities Capital expenditures Security deposits and other Net cash used in investing activities Proceeds from borrowings under Credit Agreement Repayments under Credit Agreement Installment loan and capital lease obligation payments Proceeds from exercise of stock options Net cash provided by (used in) financing activities Effect of exchange rate changes on cash and cash equivalents Decrease in cash and cash equivalents Disclosure Text Block [Abstract] Earnings Per Share [Abstract] Supplemental Cash Flow Elements [Abstract] Inventory Disclosure [Abstract] Schedule of inventory, current [Abstract] Raw materials Work in process Finished products Goodwill and Intangible Assets Disclosure [Abstract] Schedule of indefinite-lived intangible assets [Abstract] July 31, 2017 April 30, 2018 Finite-lived intangible assets, Gross July 31, 2017 April 30, 2018 Finite-lived intangible assets, Accumulated Amortization July 31, 2017 April 30, 2018 Finite-lived intangible assets, Net Foreign currency translation Foreign currency translation Foreign currency translation Segments [Axis] Life Sciences [Member] Schedule of intangible assets [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Customer Relationships [Member] Website And Acquired Content [Member] Licensed Technology And Other [Member] Trademarks [Member] Schedule of useful lives for acquisitions [Abstract] Useful life assigned Finite-Lived Intangible Asset, Useful Life Weighted average remaining useful life Other Intangible Assets [Member] Range [Axis] Minimum [Member] Maximum [Member] Payables and Accruals [Abstract] Accrued liabilities [Abstract] Payroll, benefits, and commissions Legal fee expense Professional fees Research and development Other Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] Schedule of other liabilities [Abstract] Long-term Debt, Type [Axis] Capital Lease Obligations [Member] Other liabilities Accrued Legal Settlement [Member] Installment Loans [Member] Stockholders' Equity Note [Abstract] Schedule of share-based compensation expense [Abstract] Class of Stock [Axis] Options [Member] Stock Based Compensation Expense Restricted Stocks [Member] Schedule of share-based compensation expense by line item [Abstract] Income Statement Location [Axis] Cost of Clinical Laboratory Services [Member] Share-based Payment Arrangement Share-based compensation Selling, General and Administrative Expenses [Member] Schedule of stock option plans [Abstract] Outstanding at July 31, 2017 Outstanding at end of period Outstanding at July 31, 2017 Outstanding at end of period Awarded Awarded Exercised Exercised Cancelled or expired Cancelled or expired Outstanding at end of period Outstanding at end of period Exercisable at end of period Exercisable at end of period Exercisable at end of period Exercisable at end of period Schedule of restricted stock awards [Abstract] Outstanding at July 31, 2017 Unvested at end of period Outstanding at July 31, 2017 Unvested at end of period Vested Vested Forfeited EX-101.PRE 11 enz-20180430_pre.xml XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Apr. 30, 2018	Jun. 01, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		47,165,942
Amendment Flag	false
Entity Central Index Key	0000316253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Apr. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Current assets:
Cash and cash equivalents	$ 62,556	$ 64,167
Accounts receivable, net of allowances	14,407	15,180
Inventories	7,278	7,047
Prepaid expenses and other	2,175	2,690
Total current assets	86,416	89,084
Property, plant and equipment, net	7,953	7,901
Goodwill	7,452	7,452
Intangible assets, net	2,149	2,895
Other assets	1,481	333
Total assets	105,451	107,665
Current liabilities:
Accounts payable – trade	8,250	10,350
Accrued liabilities	9,795	6,720
Other current liabilities	623	740
Total current liabilities	18,668	17,810
Other liabilities	404	983
Total liabilities	19,072	18,793
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 47,161,942 at April 30, 2018 and 46,506,176 at July 31, 2017	472	465
Additional paid-in capital	330,517	328,294
Accumulated deficit	(246,457)	(241,900)
Accumulated other comprehensive income	1,847	2,013
Total stockholders’ equity	86,379	88,872
Total liabilities and stockholders’ equity	$ 105,451	$ 107,665

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Apr. 30, 2018	Jul. 31, 2017
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	47,161,942	46,506,176
Common Stock, shares outstanding	47,161,942	46,506,176

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Revenues:
Revenues	$ 25,630	$ 27,089	$ 80,258	$ 79,633
Operating costs and expenses:
Research and development	799	766	2,358	2,071
Selling, general and administrative	11,025	10,534	32,986	33,246
Provision for uncollectible accounts receivable	396	620	1,989	1,968
Legal fee expense	1,651	512	3,782	1,254
Total operating costs and expenses	28,428	27,348	86,710	82,232
Operating loss	(2,798)	(259)	(6,452)	(2,599)
Other income (expense):
Interest	227	115	569	240
Other	17	(74)	86	69
Foreign exchange gain (loss)	(462)	147	143	(308)
Loss before income taxes	(3,016)	(71)	(5,654)	(2,598)
Benefit for income taxes		0	1,097	0
Net loss	$ (3,016)	$ (71)	$ (4,557)	$ (2,598)
Net loss per common share:
Basic and diluted (in Dollars per share)	$ (0.06)	$ 0.00	$ (0.10)	$ (0.06)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	47,073	46,367	46,895	46,310
Clinical Laboratory Services [Member]
Revenues:
Revenues	$ 18,137	$ 19,584	$ 58,001	$ 56,979
Operating costs and expenses:
Cost of Revenues	10,995	11,334	34,767	33,282
Product [Member]
Revenues:
Revenues	7,415	7,312	21,618	21,721
Operating costs and expenses:
Cost of Revenues	3,562	3,582	10,828	10,411
Royalty and License Fees [Member]
Revenues:
Revenues	$ 78	$ 193	$ 639	$ 933

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Net loss	$ (3,016)	$ (71)	$ (4,557)	$ (2,598)
Other comprehensive income (loss):
Foreign currency translation adjustments	329	(116)	(166)	122
Comprehensive loss	$ (2,687)	$ (187)	$ (4,723)	$ (2,476)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Apr. 30, 2018 - USD ($) $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jul. 31, 2017	$ 465		$ 328,294	$ (241,900)	$ 2,013	$ 88,872
Balance, Shares (in Shares) at Jul. 31, 2017	46,506,176
Net loss for the period ended April 30, 2018				(4,557)		(4,557)
Cashless options exercise	$ 4	$ (1,014)	1,010
Cashless options exercise, Shares (in Shares)	340,898	106,911
Vesting of restricted stock, Shares (in Shares)	2,562
Exercise of stock options	$ 3		828			$ 831
Exercise of stock options, Shares (in Shares)	274,726					615,624
Share-based compensation charges			617			$ 617
Issuance of common stock and treasury stock for employee 401(k) plan match		$ 1,014	(232)			782
Issuance of common stock and treasury stock for employee 401(k) plan match, Shares (in Shares)	37,580	(106,911)
Foreign currency translation adjustments					(166)	(166)
Balance at Apr. 30, 2018	$ 472		$ 330,517	$ (246,457)	$ 1,847	$ 86,379
Balance, Shares (in Shares) at Apr. 30, 2018	47,161,942

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Cash flows from operating activities:
Net loss	$ (4,557)	$ (2,598)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment	1,608	1,552
Amortization of intangible assets	742	1,140
Provision for uncollectible accounts receivable	1,989	1,968
Share-based compensation charges	617	601
Accrual for share-based 401(k) employer match expense	630	552
Foreign exchange (gain) loss	(149)	267
Changes in operating assets and liabilities:
Accounts receivable	(1,233)	(3,192)
Inventories	(257)	(213)
Prepaid expenses and other	513	195
Accounts payable – trade	(2,126)	(459)
Accrued liabilities, other current liabilities and other liabilities	2,846	(1,707)
Other assets	(1,098)
Total adjustments	4,082	704
Net cash used in operating activities	(475)	(1,894)
Cash flows from investing activities:
Capital expenditures	(1,626)	(1,424)
Security deposits and other	(51)	6
Net cash used in investing activities	(1,677)	(1,418)
Cash flows from financing activities:
Proceeds from borrowings under Credit Agreement		40,694
Repayments under Credit Agreement		(42,250)
Installment loan and capital lease obligation payments	(299)	(428)
Proceeds from exercise of stock options	831	159
Net cash provided by (used in) financing activities	532	(1,825)
Effect of exchange rate changes on cash and cash equivalents	9	(13)
Decrease in cash and cash equivalents	(1,611)	(5,150)
Cash and cash equivalents - beginning of period	64,167	67,777
Cash and cash equivalents - end of period	$ 62,556	$ 62,627

XML 19 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Apr. 30, 2018

Disclosure Text Block [Abstract]

Basis of Accounting [Text Block]

Note 1 – Basis of Presentation

Effect of New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Pronouncements Issued but Not Yet Adopted

We will recognize expense in the consolidated statement of operations similar to current lease accounting, in the cost of sales and selling, general and administrative.

We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations.

Concentration Risk

XML 20 R9.htm IDEA: XBRL DOCUMENT

Net income (loss) per share

9 Months Ended

Apr. 30, 2018

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 2 – Net income (loss) per share

XML 21 R10.htm IDEA: XBRL DOCUMENT

Supplemental disclosure for statement of cash flows

9 Months Ended

Apr. 30, 2018

Supplemental Cash Flow Elements [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]

Note 3 - Supplemental disclosure for statement of cash flows

For the nine months ended April 30, 2018 and 2017, income taxes paid by the Company were $65 and $1,021, respectively.

For the nine months ended April 30, 2018 and 2017, interest paid by the Company was $61 and $99, respectively.

For the nine months ended April 30, 2018 and 2017, the Company financed $0 and $69 respectively, in machinery and transportation equipment under installment loans.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Apr. 30, 2018

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

Note 4 – Inventories

Inventories consist of the following:

	April 30, 2018		July 31, 2017
Raw materials	$	817	$	852
Work in process		2,065		1,905
Finished products		4,396		4,290
	$	7,278	$	7,047

XML 23 R12.htm IDEA: XBRL DOCUMENT

Goodwill and intangible assets

9 Months Ended

Apr. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

Note 5 – Goodwill and intangible assets

At April 30, 2018 and July 31, 2017, the Company’s carrying amount of goodwill, related to the Clinical Labs segment, is $7,452.

The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows:

	Gross		Accumulated Amortization			Net
July 31, 2017	$	27,436	$	(24,541	)	$	2,895
Amortization expense		—		(742	)		(742	)
Foreign currency translation		2		(6	)		(4	)
April 30, 2018	$	27,438	$	(25,289	)	$	2,149

Intangible assets, all finite lived, consist of the following:

	April 30, 2018							July 31, 2017
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Patents	$	11,027	$	(10,971	)	$	56	$	11,027	$	(10,951	)	$	76
Customer relationships		11,892		(9,799	)		2,093		11,881		(9,083	)		2,798
Website and acquired content		1,010		(1,010	)		—		1,011		(1,011	)		—
Licensed technology and other		492		(492	)		—		484		(463	)		21
Trademarks		3,017		(3,017	)		—		3,033		(3,033	)		—
Total	$	27,438	$	(25,289	)	$	2,149	$	27,436	$	(24,541	)	$	2,895

At April 30, 2018, information with respect to intangibles assets acquired is as follows:

	Useful life assigned	Weighted average remaining useful life
Customer relationships	8 -15 years	2.5 years
Other intangibles	10 years	1.5 years

At April 30, 2018, the weighted average remaining useful life of intangible assets is approximately two years.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

9 Months Ended

Apr. 30, 2018

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 6 – Accrued Liabilities

Accrued liabilities consist of the following:

	April 30, 2018		July 31, 2017
Payroll, benefits, and commissions	$	4,343	$	4,092
Legal fee expense		2,401		599
Professional fees		764		442
Research and development		—		143
Other		2,287		1,444
	$	9,795	$	6,720

At April 30, 2018, other accrued liabilities primarily include $400 for a legal settlement.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Other Liabilities

9 Months Ended

Apr. 30, 2018

Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]

Other Liabilities Disclosure [Text Block]

Note 7 – Other Liabilities

Other liabilities consist of the following:

	April 30, 2018		July 31, 2017
Capital lease obligations, net of short term	$	397	$	551
Accrued legal settlement		—		410
Installment loans, net of short term		7		22
	$	404	$	983

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Apr. 30, 2018

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 8 – Stockholders’ Equity

Controlled Equity Offering

During the nine months ended April 30, 2018 and during fiscal 2017, the Company did not sell any shares of Common Stock under the Sales Agreement.

Treasury stock

Share-based compensation

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended April 30,				Nine months ended April 30,
	2018		2017		2018		2017
Stock options	$	202	$	204	$	609	$	586
Restricted stock		2		5		8		15
	$	204	$	209	$	617	$	601

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended April 30,				Nine months ended April 30,
	2018		2017		2018		2017
Cost of clinical laboratory services	$	—	$	2	$	—	$	5
Selling, general and administrative		204		207		617		596
	$	204	$	209	$	617	$	601

No excess tax benefits were recognized during the nine month periods ended April 30, 2018 and 2017.

Stock Option Plans

The following table summarizes stock option activity during the nine month period ended April 30, 2018:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2017		2,130,995		$	4.26
Awarded		117,580		$	8.36
Exercised		(615,624	)	$	2.99		$	5,896
Cancelled or expired		(29,334	)	$	5.94
Outstanding at end of period		1,603,617		$	5.02	2.6 years	$	4,344
Exercisable at end of period		1,168,489		$	4.25	1.2 years	$	2,261

Restricted Stock Awards

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2017		7,436		$	4.45
Awarded		—			—
Vested		(2,562	)	$	(5.51	)
Forfeited		(386	)		(5.62	)
Unvested at end of period		4,488		$	2.97

The fair value of the awards that vested during the nine months ended April 30, 2018 and 2017 was $22 and $19, respectively.

The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 2,266,800 shares as of April 30, 2018.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income taxes

9 Months Ended

Apr. 30, 2018

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note 9 – Income taxes

The Company’s effective tax rate benefit for the three and nine months ended April 30, 2018 was zero and 24.1%, respectfully and was based on the refundable federal AMT credit. There was no tax provision or benefit for the 2017 periods. The Company’s effective tax rate for all periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Segment reporting

9 Months Ended

Apr. 30, 2018

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Note 10 – Segment reporting

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2018
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,137			—			—			—		$	18,137
Product revenues		—		$	7,415			—			—			7,415
Royalty and license fee income		—			78			—			—			78
		18,137			7,493			—			—			25,630
Operating costs and expenses:
Cost of clinical laboratory services		10,995			—			—			—			10,995
Cost of product revenues		—			3,562			—			—			3,562
Research and development		—			576		$	223			—			799
Selling, general and administrative		6,252			2,974			—		$	1,799			11,025
Provision for uncollectible accounts receivable		400			(4	)		—			—			396
Legal fee expense		25			19			—			1,607			1,651
Total operating costs and expenses		17,672			7,127			223			3,406			28,428

Operating income (loss)		465			366			(223	)		(3,406	)		(2,798	)

Other income (expense):
Interest		(22	)		12			—			237			227
Other		15			2			—			—			17
Foreign exchange loss		—			(462	)		—			—			(462	)
Income (loss) before income taxes	$	458		$	(82	)	$	(223	)	$	(3,169	)	$	(3,016	)

Depreciation and amortization included above	$	437		$	358		$	—		$	20		$	815

Share-based compensation included in above:
Selling, general and administrative		26		$	17			—		$	161			204
Total	$	26		$	17		$	—		$	161		$	204

Capital expenditures	$	465		$	96		$	—		$	—		$	561

Three months ended April 30, 2017
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	19,584			—			—			—		$	19,584
Product revenues		—		$	7,312			—			—			7,312
Royalty and license fee income		—			193			—			—			193
		19,584			7,505			—			—			27,089
Operating costs and expenses:
Cost of clinical laboratory services		11,334			—			—			—			11,334
Cost of product revenues		—			3,582			—			—			3,582
Research and development		—			552		$	214			—			766
Selling, general and administrative		6,118			2,745			—		$	1,671			10,534
Provision for uncollectible accounts receivable		650			(30	)		—			—			620
Legal fee expense		4			42			—			466			512
Total operating costs and expenses		18,106			6,891			214			2,137			27,348

Operating income (loss)		1,478			614			(214	)		(2,137	)		(259	)

Other income (expense):
Interest		(28	)		12			—			131			115
Other		7			(98	)		—			17			(74	)
Foreign exchange gain		—			147			—			—			147
Income (loss) before income taxes	$	1,457		$	675		$	(214	)	$	(1,989	)	$	(71	)

Depreciation and amortization included above	$	390		$	423		$	—		$	37		$	850

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Selling, general and administrative		38		$	23			—		$	146			207
Total	$	40		$	23		$	—		$	146		$	209

Capital expenditures	$	483		$	252		$	—		$	—		$	735

Nine months ended April 30, 2018
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	58,001			—			—			—		$	58,001
Product revenues		—		$	21,618			—			—			21,618
Royalty and license fee income		—			639			—			—			639
		58,001			22,257			—			—			80,258
Operating costs and expenses:
Cost of clinical laboratory services		34,767			—			—			—			34,767
Cost of product revenues		—			10,828			—			—			10,828
Research and development		—			1,690		$	668			—			2,358
Selling, general and administrative		18,454			8,487			—		$	6,045			32,986
Provision for uncollectible accounts receivable		2,000			(11	)		—			—			1,989
Legal fee expense		46			47			—			3,689			3,782
Total operating costs and expenses		55,267			21,041			668			9,734			86,710

Operating income (loss)		2,734			1,216			(668	)		(9,734	)		(6,452	)

Other income (expense):
Interest		(70	)		35			—			604			569
Other		32			10			—			44			86
Foreign exchange gain		—			143			—			—			143
Income (loss) before income taxes	$	2,696		$	1,404		$	(668	)	$	(9,086	)	$	(5,654	)

Depreciation and amortization included above	$	1,254		$	1,039		$	—		$	57		$	2,350

Share-based compensation included in above:
Selling, general and administrative		86		$	61			—		$	470			617
Total	$	86		$	61		$	—		$	470		$	617

Capital expenditures	$	1,459		$	167		$	—		$	—		$	1,626

Nine months ended April 30, 2017
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	56,979			—			—			—		$	56,979
Product revenues		—		$	21,721			—			—			21,721
Royalty and license fee income		—			933			—			—			933
		56,979			22,654			—			—			79,633
Operating costs and expenses:
Cost of clinical laboratory services		33,282			—			—			—			33,282
Cost of product revenues		—			10,411			—			—			10,411
Research and development		—			1,695		$	376			—			2,071
Selling, general and administrative		17,967			8,596			—		$	6,683			33,246
Provision for uncollectible accounts receivable		1,910			58			—			—			1,968
Legal fee expense		105			70			—			1,079			1,254
Total operating costs and expenses		53,264			20,830			376			7,762			82,232

Operating income (loss)		3,715			1,824			(376	)		(7,657	)		(2,599	)

Other income (expense):
Interest		(85	)		34			—			291			240
Other		126			(98	)		—			41			69
Foreign exchange loss		—			(308	)		—			—			(308	)
Income (loss) before income taxes	$	3,756		$	1,452		$	(376	)	$	(7,430	)	$	(2,598	)

Depreciation and amortization included above	$	1,185		$	1,432		$	—		$	75		$	2,692

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Selling, general and administrative		74		$	49			—		$	473			596
Total	$	79		$	49		$	—		$	473		$	601

Capital expenditures	$	1,070		$	354		$	—		$	—		$	1,424

XML 29 R18.htm IDEA: XBRL DOCUMENT

Contingencies

9 Months Ended

Apr. 30, 2018

Loss Contingency [Abstract]

Contingencies Disclosure [Text Block]

Note 11 – Contingencies

XML 30 R19.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Apr. 30, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires all excess tax benefits or deficiencies to be recognized as income tax expense or benefit in the income statement. In addition, excess tax benefits should be classified along with other income tax cash flows as an operating activity in the statement of cash flows. We adopted this standard as of August 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial statements.
Pronouncements Issued but Not Yet Adopted [Policy Text Block]	Pronouncements Issued but Not Yet Adopted In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606. ASU 2014-09 and its amendments supersede the current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue recognition standard is to require an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled to in exchange for the goods or services it transfers control of to its customers. The standard will be effective for our fiscal year beginning August 1, 2018 and its interim periods. We are not early adopting. We expect to use the full retrospective method upon adoption by applying the standard to each prior reporting period presented. We continue to evaluate the expected impact of the standard. Based on our preliminary assessment of the standard, we expect that the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be considered an implicit price concession in determining net revenues. Accordingly, we expect to report the estimate of uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within operating costs and expenses. The adoption of this standard will also result in increased disclosure, including qualitative and quantitative disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts from customers. However, the adoption of this standard is not expected to have a material impact on our financial position or cash flows. In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for our fiscal year beginning August 1, 2019 including interim periods within that fiscal year. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We believe the adoption of this standard would materially impact our consolidated financial statements by significantly increasing our non-current assets and non-current liabilities on our consolidated balance sheets if we record the right of use assets and related lease liabilities for our existing operating leases. We will recognize expense in the consolidated statement of operations similar to current lease accounting, in the cost of sales and selling, general and administrative. In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326). This standard changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a new forward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoption of this standard is required for our annual and interim periods beginning August 1, 2020 and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial position and cash flows. In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption of this standard is required for our annual and interim periods beginning August 1, 2018 with the amendments in the update applied prospectively to an award modified on or after the adoption date. In May 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, regarding the accounting implications of the recently issued Tax Cuts and Jobs Act (the “Act”). This standard is effective immediately. The update clarifies that in a company’s financial statements that include the reporting period in which the Act was enacted, the company must first reflect the income tax effects of the Act in which the accounting under GAAP is complete. These amounts would not be provisional amounts. The company would also report provisional amounts for those specific income tax effects for which the accounting under GAAP is incomplete but a reasonable estimate can be determined. We have recorded a provisional amount which we believe is a reasonable estimate of the effects of the Act on our financial statements as of April 30, 2018. Technical corrections or other forthcoming guidance could change how we interpret provisions of the Act, which may impact our effective tax rate and could affect our deferred tax assets, tax positions and/or our tax liabilities.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	*Concentration Risk* Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 40% and 38% of the Clinical Labs segment net revenue for the three months ended April 30, 2018 and 2017 respectively, and 39% and 38% for the nine months ended April 30, 2018 and 2017, respectively.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Apr. 30, 2018

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consist of the following:

	April 30, 2018		July 31, 2017
Raw materials	$	817	$	852
Work in process		2,065		1,905
Finished products		4,396		4,290
	$	7,278	$	7,047

XML 32 R21.htm IDEA: XBRL DOCUMENT

Goodwill and intangible assets (Tables)

9 Months Ended

Apr. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Indefinite-Lived Intangible Assets [Table Text Block]

The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows:

	Gross		Accumulated Amortization			Net
July 31, 2017	$	27,436	$	(24,541	)	$	2,895
Amortization expense		—		(742	)		(742	)
Foreign currency translation		2		(6	)		(4	)
April 30, 2018	$	27,438	$	(25,289	)	$	2,149

Schedule of Intangible Assets [Table Text Block]

Intangible assets, all finite lived, consist of the following:

	April 30, 2018							July 31, 2017
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Patents	$	11,027	$	(10,971	)	$	56	$	11,027	$	(10,951	)	$	76
Customer relationships		11,892		(9,799	)		2,093		11,881		(9,083	)		2,798
Website and acquired content		1,010		(1,010	)		—		1,011		(1,011	)		—
Licensed technology and other		492		(492	)		—		484		(463	)		21
Trademarks		3,017		(3,017	)		—		3,033		(3,033	)		—
Total	$	27,438	$	(25,289	)	$	2,149	$	27,436	$	(24,541	)	$	2,895

Schedule of Useful Lives For Acquisitions [Table Text Block]

At April 30, 2018, information with respect to intangibles assets acquired is as follows:

	Useful life assigned	Weighted average remaining useful life
Customer relationships	8 -15 years	2.5 years
Other intangibles	10 years	1.5 years

XML 33 R22.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

9 Months Ended

Apr. 30, 2018

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following:

	April 30, 2018		July 31, 2017
Payroll, benefits, and commissions	$	4,343	$	4,092
Legal fee expense		2,401		599
Professional fees		764		442
Research and development		—		143
Other		2,287		1,444
	$	9,795	$	6,720

XML 34 R23.htm IDEA: XBRL DOCUMENT

Other Liabilities (Tables)

9 Months Ended

Apr. 30, 2018

Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]

Schedule of Other Liabilities [Table Text Block]

Other liabilities consist of the following:

	April 30, 2018		July 31, 2017
Capital lease obligations, net of short term	$	397	$	551
Accrued legal settlement		—		410
Installment loans, net of short term		7		22
	$	404	$	983

XML 35 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Apr. 30, 2018

Stockholders' Equity Note [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended April 30,				Nine months ended April 30,
	2018		2017		2018		2017
Stock options	$	202	$	204	$	609	$	586
Restricted stock		2		5		8		15
	$	204	$	209	$	617	$	601

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended April 30,				Nine months ended April 30,
	2018		2017		2018		2017
Cost of clinical laboratory services	$	—	$	2	$	—	$	5
Selling, general and administrative		204		207		617		596
	$	204	$	209	$	617	$	601

Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity during the nine month period ended April 30, 2018:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2017		2,130,995		$	4.26
Awarded		117,580		$	8.36
Exercised		(615,624	)	$	2.99		$	5,896
Cancelled or expired		(29,334	)	$	5.94
Outstanding at end of period		1,603,617		$	5.02	2.6 years	$	4,344
Exercisable at end of period		1,168,489		$	4.25	1.2 years	$	2,261

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2017		7,436		$	4.45
Awarded		—			—
Vested		(2,562	)	$	(5.51	)
Forfeited		(386	)		(5.62	)
Unvested at end of period		4,488		$	2.97

XML 36 R25.htm IDEA: XBRL DOCUMENT

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2018
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,137			—			—			—		$	18,137
Product revenues		—		$	7,415			—			—			7,415
Royalty and license fee income		—			78			—			—			78
		18,137			7,493			—			—			25,630
Operating costs and expenses:
Cost of clinical laboratory services		10,995			—			—			—			10,995
Cost of product revenues		—			3,562			—			—			3,562
Research and development		—			576		$	223			—			799
Selling, general and administrative		6,252			2,974			—		$	1,799			11,025
Provision for uncollectible accounts receivable		400			(4	)		—			—			396
Legal fee expense		25			19			—			1,607			1,651
Total operating costs and expenses		17,672			7,127			223			3,406			28,428

Operating income (loss)		465			366			(223	)		(3,406	)		(2,798	)

Other income (expense):
Interest		(22	)		12			—			237			227
Other		15			2			—			—			17
Foreign exchange loss		—			(462	)		—			—			(462	)
Income (loss) before income taxes	$	458		$	(82	)	$	(223	)	$	(3,169	)	$	(3,016	)

Depreciation and amortization included above	$	437		$	358		$	—		$	20		$	815

Share-based compensation included in above:
Selling, general and administrative		26		$	17			—		$	161			204
Total	$	26		$	17		$	—		$	161		$	204

Capital expenditures	$	465		$	96		$	—		$	—		$	561

Three months ended April 30, 2017
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	19,584			—			—			—		$	19,584
Product revenues		—		$	7,312			—			—			7,312
Royalty and license fee income		—			193			—			—			193
		19,584			7,505			—			—			27,089
Operating costs and expenses:
Cost of clinical laboratory services		11,334			—			—			—			11,334
Cost of product revenues		—			3,582			—			—			3,582
Research and development		—			552		$	214			—			766
Selling, general and administrative		6,118			2,745			—		$	1,671			10,534
Provision for uncollectible accounts receivable		650			(30	)		—			—			620
Legal fee expense		4			42			—			466			512
Total operating costs and expenses		18,106			6,891			214			2,137			27,348

Operating income (loss)		1,478			614			(214	)		(2,137	)		(259	)

Other income (expense):
Interest		(28	)		12			—			131			115
Other		7			(98	)		—			17			(74	)
Foreign exchange gain		—			147			—			—			147
Income (loss) before income taxes	$	1,457		$	675		$	(214	)	$	(1,989	)	$	(71	)

Depreciation and amortization included above	$	390		$	423		$	—		$	37		$	850

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Selling, general and administrative		38		$	23			—		$	146			207
Total	$	40		$	23		$	—		$	146		$	209

Capital expenditures	$	483		$	252		$	—		$	—		$	735

Nine months ended April 30, 2018
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	58,001			—			—			—		$	58,001
Product revenues		—		$	21,618			—			—			21,618
Royalty and license fee income		—			639			—			—			639
		58,001			22,257			—			—			80,258
Operating costs and expenses:
Cost of clinical laboratory services		34,767			—			—			—			34,767
Cost of product revenues		—			10,828			—			—			10,828
Research and development		—			1,690		$	668			—			2,358
Selling, general and administrative		18,454			8,487			—		$	6,045			32,986
Provision for uncollectible accounts receivable		2,000			(11	)		—			—			1,989
Legal fee expense		46			47			—			3,689			3,782
Total operating costs and expenses		55,267			21,041			668			9,734			86,710

Operating income (loss)		2,734			1,216			(668	)		(9,734	)		(6,452	)

Other income (expense):
Interest		(70	)		35			—			604			569
Other		32			10			—			44			86
Foreign exchange gain		—			143			—			—			143
Income (loss) before income taxes	$	2,696		$	1,404		$	(668	)	$	(9,086	)	$	(5,654	)

Depreciation and amortization included above	$	1,254		$	1,039		$	—		$	57		$	2,350

Share-based compensation included in above:
Selling, general and administrative		86		$	61			—		$	470			617
Total	$	86		$	61		$	—		$	470		$	617

Capital expenditures	$	1,459		$	167		$	—		$	—		$	1,626

Nine months ended April 30, 2017
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	56,979			—			—			—		$	56,979
Product revenues		—		$	21,721			—			—			21,721
Royalty and license fee income		—			933			—			—			933
		56,979			22,654			—			—			79,633
Operating costs and expenses:
Cost of clinical laboratory services		33,282			—			—			—			33,282
Cost of product revenues		—			10,411			—			—			10,411
Research and development		—			1,695		$	376			—			2,071
Selling, general and administrative		17,967			8,596			—		$	6,683			33,246
Provision for uncollectible accounts receivable		1,910			58			—			—			1,968
Legal fee expense		105			70			—			1,079			1,254
Total operating costs and expenses		53,264			20,830			376			7,762			82,232

Operating income (loss)		3,715			1,824			(376	)		(7,657	)		(2,599	)

Other income (expense):
Interest		(85	)		34			—			291			240
Other		126			(98	)		—			41			69
Foreign exchange loss		—			(308	)		—			—			(308	)
Income (loss) before income taxes	$	3,756		$	1,452		$	(376	)	$	(7,430	)	$	(2,598	)

Depreciation and amortization included above	$	1,185		$	1,432		$	—		$	75		$	2,692

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Selling, general and administrative		74		$	49			—		$	473			596
Total	$	79		$	49		$	—		$	473		$	601

Capital expenditures	$	1,070		$	354		$	—		$	—		$	1,424

XML 37 R26.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details)	3 Months Ended		9 Months Ended
Basis of Presentation (Details)	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Sales Revenue, Net [Member] \| Clinical Labs [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage	40.00%	38.00%	39.00%	38.00%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Net income (loss) per share (Details) - shares	3 Months Ended		9 Months Ended
Net income (loss) per share (Details) - shares	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Unvested Restricted Stock [Member] \| In the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	431,000		694,000
Weighted Average Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		987,000		865,000
Outstanding Options [Member] \| Out of the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	581,000	0	194,000	165,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Jul. 31, 2017
Supplemental disclosure for statement of cash flows (Details) [Line Items]
Income Taxes Paid	$ 65	$ 1,021
Interest Paid	61	99
Installment Loans Financed Amount	$ 0	69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	615,624
Stock Issued During Period, Value, Employee Benefit Plan	$ 782	$ 724	$ 724
Officer [Member]
Supplemental disclosure for statement of cash flows (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	340,898
Treasury Stock, Shares, Acquired (in Shares)	106,911
Treasury Stock, Value, Acquired, Cost Method	$ 1,014

XML 40 R29.htm IDEA: XBRL DOCUMENT

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Schedule of inventory, current [Abstract]
Raw materials	$ 817	$ 852
Work in process	2,065	1,905
Finished products	4,396	4,290
	$ 7,278	$ 7,047

XML 41 R30.htm IDEA: XBRL DOCUMENT

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2018	Jul. 31, 2017
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	2 years
Clinical Labs [Member]
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452

XML 42 R31.htm IDEA: XBRL DOCUMENT

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Indefinite-lived Intangible Assets [Line Items]
July 31, 2017	$ 27,436
July 31, 2017	24,541
July 31, 2017	2,895
Amortization expense	742	$ 1,140
Amortization expense	742	$ 1,140
April 30, 2018	27,438
April 30, 2018	25,289
April 30, 2018	2,149
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
July 31, 2017	27,436
July 31, 2017	(24,541)
July 31, 2017	2,895
Amortization expense	(742)
Amortization expense	(742)
Foreign currency translation	2
Foreign currency translation	(6)
Foreign currency translation	(4)
April 30, 2018	27,438
April 30, 2018	(25,289)
April 30, 2018	$ 2,149

XML 43 R32.htm IDEA: XBRL DOCUMENT

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,438	$ 27,436
Finite-lived intangible assets, Accumulated Amortization	(25,289)	(24,541)
Finite-lived intangible assets, Net	2,149	2,895
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(10,971)	(10,951)
Finite-lived intangible assets, Net	56	76
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,892	11,881
Finite-lived intangible assets, Accumulated Amortization	(9,799)	(9,083)
Finite-lived intangible assets, Net	2,093	2,798
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,010	1,011
Finite-lived intangible assets, Accumulated Amortization	(1,010)	(1,011)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	492	484
Finite-lived intangible assets, Accumulated Amortization	(492)	(463)
Finite-lived intangible assets, Net		21
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	3,017	3,033
Finite-lived intangible assets, Accumulated Amortization	$ (3,017)	$ (3,033)

XML 44 R33.htm IDEA: XBRL DOCUMENT

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	9 Months Ended
	Apr. 30, 2018
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	2 years 6 months
Customer Relationships [Member] \| Minimum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Customer Relationships [Member] \| Maximum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	1 year 6 months

XML 45 R34.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Details) $ in Thousands	Apr. 30, 2018 USD ($)
Payables and Accruals [Abstract]
Accrued Legal Settlement Current	$ 400

XML 46 R35.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Details) - Accrued liabilities - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 4,343	$ 4,092
Legal fee expense	2,401	599
Professional fees	764	442
Research and development		143
Other	2,287	1,444
	$ 9,795	$ 6,720

XML 47 R36.htm IDEA: XBRL DOCUMENT

Other Liabilities (Details) $ in Thousands	Apr. 30, 2018 USD ($)
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Capital Leases, Future Minimum Payments, Interest Included in Payments	$ 75
Capital Lease Obligations	570
Capital Lease Obligations, Current	173
Long-term Debt	44
Long-term Debt, Current Maturities	$ 37

XML 48 R37.htm IDEA: XBRL DOCUMENT

Other Liabilities (Details) - Schedule of other liabilities - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 404	$ 983
Capital Lease Obligations [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	397	551
Accrued Legal Settlement [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities		410
Installment Loans [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 7	$ 22

XML 49 R38.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($)	9 Months Ended		12 Months Ended
Stockholders' Equity (Details) - USD ($)	Apr. 30, 2018	Apr. 30, 2017	Jul. 31, 2017	Dec. 31, 2014
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01		$ 0.01
Percentage of Commission Payable on Equity Offering	3.00%
Maximum Offering Price Under Sales Agreement	$ 20,000,000			$ 20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	615,624
Excess Tax Benefit from Share-based Compensation, Financing Activities	$ 0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	14 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 22,000	19,000
Stock Issued During Period, Value, Employee Benefit Plan	782,000	$ 724,000	$ 724,000
Restricted Stock [Member]
Stockholders' Equity (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 100,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms	22 months
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	5,000,000		3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	2,266,800
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Authorized Common Stock That May Be Issued And Sold Under Sales Agreement	$ 19,150,000
Securities That May Be Sold Under The Agreement	$ 150,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	274,726
Treasury Stock, Shares, Acquired (in Shares)	340,898
Treasury Stock, Value, Acquired, Cost Method	$ 4,000
Stock Issued During Period, Shares, Employee Benefit Plan (in Shares)	37,580	91,541
Treasury Stock [Member]
Stockholders' Equity (Details) [Line Items]
Treasury Stock, Shares, Acquired (in Shares)	106,911
Treasury Stock, Value, Acquired, Cost Method	$ (1,014,000)
Stock Issued During Period, Value, Employee Benefit Plan	$ 1,014,000
Stock Issued During Period, Shares, Employee Benefit Plan (in Shares)	(106,911)
Officer [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	340,898
Treasury Stock, Shares, Acquired (in Shares)	106,911
Treasury Stock, Value, Acquired, Cost Method	$ 1,014,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 204	$ 209	$ 617	$ 601
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	202	204	609	586
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 2	$ 5	$ 8	$ 15

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 204	$ 209	$ 617	$ 601
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement		2		5
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 204	$ 207	$ 617	$ 596

XML 52 R41.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of stock option plans $ / shares in Units, $ in Thousands	9 Months Ended
	Apr. 30, 2018 USD ($) $ / shares shares
Schedule of stock option plans [Abstract]
Outstanding at July 31, 2017 \| shares	2,130,995
Outstanding at July 31, 2017 \| $ / shares	$ 4.26
Awarded \| shares	117,580
Awarded \| $ / shares	$ 8.36
Exercised \| shares	(615,624)
Exercised \| $ / shares	$ 2.99
Exercised \| $	$ 5,896
Cancelled or expired \| shares	(29,334)
Cancelled or expired \| $ / shares	$ 5.94
Outstanding at end of period \| shares	1,603,617
Outstanding at end of period \| $ / shares	$ 5.02
Outstanding at end of period	2 years 219 days
Outstanding at end of period \| $	$ 4,344
Exercisable at end of period \| shares	1,168,489
Exercisable at end of period \| $ / shares	$ 4.25
Exercisable at end of period	1 year 73 days
Exercisable at end of period \| $	$ 2,261

XML 53 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of restricted stock awards	9 Months Ended
	Apr. 30, 2018 $ / shares shares
Schedule of restricted stock awards [Abstract]
Outstanding at July 31, 2017 \| shares	7,436
Outstanding at July 31, 2017 \| $ / shares	$ 4.45
Vested \| shares	(2,562)
Vested \| $ / shares	$ (5.51)
Forfeited \| shares	(386)
Forfeited \| $ / shares	$ (5.62)
Unvested at end of period \| shares	4,488
Unvested at end of period \| $ / shares	$ 2.97

XML 54 R43.htm IDEA: XBRL DOCUMENT

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended		5 Months Ended	7 Months Ended	9 Months Ended
Income taxes (Details) - USD ($) $ in Thousands	Apr. 30, 2018	Apr. 30, 2017	Dec. 31, 2017	Jul. 31, 2018	Apr. 30, 2018	Apr. 30, 2017
Income taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			35.00%
Effective Income Tax Rate Reconciliation, Percent	0.00%				24.10%
Income Tax Expense (Benefit) (in Dollars)		$ 0			$ (1,097)	$ 0
Scenario, Plan [Member]
Income taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				21.00%
Alternate Minimum Tax [Member]
Income taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, Tax Credit, Amount (in Dollars)					$ 1,100

XML 55 R44.htm IDEA: XBRL DOCUMENT

Segment reporting (Details)	9 Months Ended
Segment reporting (Details)	Apr. 30, 2018
Segment Reporting [Abstract]
Number of Reportable Segments	3

XML 56 R45.htm IDEA: XBRL DOCUMENT

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Segment Reporting Information [Line Items]
Revenues	$ 25,630	$ 27,089	$ 80,258	$ 79,633
Research and development	799	766	2,358	2,071
Selling, general and administrative	11,025	10,534	32,986	33,246
Provision for uncollectible accounts receivable	396	620	1,989	1,968
Legal fee expense	1,651	512	3,782	1,254
Operating income (loss)	(2,798)	(259)	(6,452)	(2,599)
Other	17	(74)	86	69
Foreign exchange gain (loss)	(462)	147	143	(308)
Share-based compensation	204	209	617	601
Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	204	207	617	596
Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation		2		5
Clinical Labs [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Selling, general and administrative	6,252	6,118	18,454	17,967
Provision for uncollectible accounts receivable	400	650	2,000	1,910
Legal fee expense	25	4	46	105
Total operating costs and expenses	17,672	18,106	55,267	53,264
Operating income (loss)	465	1,478	2,734	3,715
Interest	(22)	(28)	(70)	(85)
Other	15	7	32	126
Income (loss) before income taxes	458	1,457	2,696	3,756
Depreciation and amortization included above	437	390	1,254	1,185
Capital expenditures	465	483	1,459	1,070
Clinical Labs [Member] \| Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	26	38	86	74
Clinical Labs [Member] \| Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	26	40	86	79
Clinical Labs [Member] \| Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation		2		5
Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenues	7,493	7,505	22,257	22,654
Research and development	576	552	1,690	1,695
Selling, general and administrative	2,974	2,745	8,487	8,596
Provision for uncollectible accounts receivable	(4)	(30)	(11)	58
Legal fee expense	19	42	47	70
Total operating costs and expenses	7,127	6,891	21,041	20,830
Operating income (loss)	366	614	1,216	1,824
Interest	12	12	35	34
Other	2	(98)	10	(98)
Foreign exchange gain (loss)	(462)	147	143	(308)
Income (loss) before income taxes	(82)	675	1,404	1,452
Depreciation and amortization included above	358	423	1,039	1,432
Capital expenditures	96	252	167	354
Life Sciences [Member] \| Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	17	23	61	49
Life Sciences [Member] \| Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	17	23	61	49
Therapeutics [Member]
Segment Reporting Information [Line Items]
Research and development	223	214	668	376
Total operating costs and expenses	223	214	668	376
Operating income (loss)	(223)	(214)	(668)	(376)
Income (loss) before income taxes	(223)	(214)	(668)	(376)
Other Segments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	1,799	1,671	6,045	6,683
Legal fee expense	1,607	466	3,689	1,079
Total operating costs and expenses	3,406	2,137	9,734	7,762
Operating income (loss)	(3,406)	(2,137)	(9,734)	(7,657)
Interest	237	131	604	291
Other		17	44	41
Income (loss) before income taxes	(3,169)	(1,989)	(9,086)	(7,430)
Depreciation and amortization included above	20	37	57	75
Other Segments [Member] \| Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	161	146	470	473
Other Segments [Member] \| Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	161	146	470	473
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	25,630	27,089	80,258	79,633
Research and development	799	766	2,358	2,071
Selling, general and administrative	11,025	10,534	32,986	33,246
Provision for uncollectible accounts receivable	396	620	1,989	1,968
Legal fee expense	1,651	512	3,782	1,254
Total operating costs and expenses	28,428	27,348	86,710	82,232
Operating income (loss)	(2,798)	(259)	(6,452)	(2,599)
Interest	227	115	569	240
Other	17	(74)	86	69
Foreign exchange gain (loss)	(462)	147	143	(308)
Income (loss) before income taxes	(3,016)	(71)	(5,654)	(2,598)
Depreciation and amortization included above	815	850	2,350	2,692
Capital expenditures	561	735	1,626	1,424
Consolidated [Member] \| Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	204	207	617	596
Consolidated [Member] \| Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	204	209	617	601
Consolidated [Member] \| Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation		2		5
Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Cost of Revenues	10,995	11,334	34,767	33,282
Clinical Laboratory Services [Member] \| Clinical Labs [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Cost of Revenues	10,995	11,334	34,767	33,282
Clinical Laboratory Services [Member] \| Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Cost of Revenues	10,995	11,334	34,767	33,282
Product [Member]
Segment Reporting Information [Line Items]
Revenues	7,415	7,312	21,618	21,721
Cost of Revenues	3,562	3,582	10,828	10,411
Product [Member] \| Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenues	7,415	7,312	21,618	21,721
Cost of Revenues	3,562	3,582	10,828	10,411
Product [Member] \| Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	7,415	7,312	21,618	21,721
Cost of Revenues	3,562	3,582	10,828	10,411
Royalty and License Fees [Member]
Segment Reporting Information [Line Items]
Revenues	78	193	639	933
Royalty and License Fees [Member] \| Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenues	78	193	639	933
Royalty and License Fees [Member] \| Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	$ 78	$ 193	$ 639	$ 933

XML 57 R46.htm IDEA: XBRL DOCUMENT

Contingencies (Details)	9 Months Ended
Contingencies (Details)	Apr. 30, 2018
Loss Contingency [Abstract]
Number Of Pending Cases	7
Loss Contingency Number Of New Defendants	2

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 175 193 1 false 41 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.enzo.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.enzo.com/role/ConsolidatedBalanceSheet CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.enzo.com/role/ConsolidatedBalanceSheet_Parentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.enzo.com/role/ConsolidatedIncomeStatement CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.enzo.com/role/ConsolidatedComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.enzo.com/role/ShareholdersEquityType2or3 CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.enzo.com/role/ConsolidatedCashFlow CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 007 - Disclosure - Basis of Presentation Sheet http://www.enzo.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Net income (loss) per share Sheet http://www.enzo.com/role/Netincomelosspershare Net income (loss) per share Notes 9 false false R10.htm 009 - Disclosure - Supplemental disclosure for statement of cash flows Sheet http://www.enzo.com/role/Supplementaldisclosureforstatementofcashflows Supplemental disclosure for statement of cash flows Notes 10 false false R11.htm 010 - Disclosure - Inventories Sheet http://www.enzo.com/role/Inventories Inventories Notes 11 false false R12.htm 011 - Disclosure - Goodwill and intangible assets Sheet http://www.enzo.com/role/Goodwillandintangibleassets Goodwill and intangible assets Notes 12 false false R13.htm 012 - Disclosure - Accrued Liabilities Sheet http://www.enzo.com/role/AccruedLiabilities Accrued Liabilities Notes 13 false false R14.htm 013 - Disclosure - Other Liabilities Sheet http://www.enzo.com/role/OtherLiabilities Other Liabilities Notes 14 false false R15.htm 014 - Disclosure - Stockholders' Equity Sheet http://www.enzo.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 015 - Disclosure - Income taxes Sheet http://www.enzo.com/role/Incometaxes Income taxes Notes 16 false false R17.htm 016 - Disclosure - Segment reporting Sheet http://www.enzo.com/role/Segmentreporting Segment reporting Notes 17 false false R18.htm 017 - Disclosure - Contingencies Sheet http://www.enzo.com/role/Contingencies Contingencies Notes 18 false false R19.htm 018 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.enzo.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies 19 false false R20.htm 019 - Disclosure - Inventories (Tables) Sheet http://www.enzo.com/role/InventoriesTables Inventories (Tables) Tables http://www.enzo.com/role/Inventories 20 false false R21.htm 020 - Disclosure - Goodwill and intangible assets (Tables) Sheet http://www.enzo.com/role/GoodwillandintangibleassetsTables Goodwill and intangible assets (Tables) Tables http://www.enzo.com/role/Goodwillandintangibleassets 21 false false R22.htm 021 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.enzo.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.enzo.com/role/AccruedLiabilities 22 false false R23.htm 022 - Disclosure - Other Liabilities (Tables) Sheet http://www.enzo.com/role/OtherLiabilitiesTables Other Liabilities (Tables) Tables http://www.enzo.com/role/OtherLiabilities 23 false false R24.htm 023 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.enzo.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.enzo.com/role/StockholdersEquity 24 false false R25.htm 024 - Disclosure - Segment reporting (Tables) Sheet http://www.enzo.com/role/SegmentreportingTables Segment reporting (Tables) Tables http://www.enzo.com/role/Segmentreporting 25 false false R26.htm 025 - Disclosure - Basis of Presentation (Details) Sheet http://www.enzo.com/role/BasisofPresentationDetails Basis of Presentation (Details) Details http://www.enzo.com/role/BasisofPresentation 26 false false R27.htm 026 - Disclosure - Net income (loss) per share (Details) Sheet http://www.enzo.com/role/NetincomelosspershareDetails Net income (loss) per share (Details) Details http://www.enzo.com/role/Netincomelosspershare 27 false false R28.htm 027 - Disclosure - Supplemental disclosure for statement of cash flows (Details) Sheet http://www.enzo.com/role/SupplementaldisclosureforstatementofcashflowsDetails Supplemental disclosure for statement of cash flows (Details) Details http://www.enzo.com/role/Supplementaldisclosureforstatementofcashflows 28 false false R29.htm 028 - Disclosure - Inventories (Details) - Schedule of inventory, current Sheet http://www.enzo.com/role/ScheduleofinventorycurrentTable Inventories (Details) - Schedule of inventory, current Details http://www.enzo.com/role/InventoriesTables 29 false false R30.htm 029 - Disclosure - Goodwill and intangible assets (Details) Sheet http://www.enzo.com/role/GoodwillandintangibleassetsDetails Goodwill and intangible assets (Details) Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 30 false false R31.htm 030 - Disclosure - Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets Sheet http://www.enzo.com/role/ScheduleofindefinitelivedintangibleassetsTable Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 31 false false R32.htm 031 - Disclosure - Goodwill and intangible assets (Details) - Schedule of intangible assets Sheet http://www.enzo.com/role/ScheduleofintangibleassetsTable Goodwill and intangible assets (Details) - Schedule of intangible assets Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 32 false false R33.htm 032 - Disclosure - Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions Sheet http://www.enzo.com/role/ScheduleofusefullivesforacquisitionsTable Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 33 false false R34.htm 033 - Disclosure - Accrued Liabilities (Details) Sheet http://www.enzo.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.enzo.com/role/AccruedLiabilitiesTables 34 false false R35.htm 034 - Disclosure - Accrued Liabilities (Details) - Accrued liabilities Sheet http://www.enzo.com/role/AccruedliabilitiesTable Accrued Liabilities (Details) - Accrued liabilities Details http://www.enzo.com/role/AccruedLiabilitiesTables 35 false false R36.htm 035 - Disclosure - Other Liabilities (Details) Sheet http://www.enzo.com/role/OtherLiabilitiesDetails Other Liabilities (Details) Details http://www.enzo.com/role/OtherLiabilitiesTables 36 false false R37.htm 036 - Disclosure - Other Liabilities (Details) - Schedule of other liabilities Sheet http://www.enzo.com/role/ScheduleofotherliabilitiesTable Other Liabilities (Details) - Schedule of other liabilities Details http://www.enzo.com/role/OtherLiabilitiesTables 37 false false R38.htm 037 - Disclosure - Stockholders' Equity (Details) Sheet http://www.enzo.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.enzo.com/role/StockholdersEquityTables 38 false false R39.htm 038 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense Sheet http://www.enzo.com/role/ScheduleofsharebasedcompensationexpenseTable Stockholders' Equity (Details) - Schedule of share-based compensation expense Details http://www.enzo.com/role/StockholdersEquityTables 39 false false R40.htm 039 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item Sheet http://www.enzo.com/role/ScheduleofsharebasedcompensationexpensebylineitemTable Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item Details http://www.enzo.com/role/StockholdersEquityTables 40 false false R41.htm 040 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option plans Sheet http://www.enzo.com/role/ScheduleofstockoptionplansTable Stockholders' Equity (Details) - Schedule of stock option plans Details http://www.enzo.com/role/StockholdersEquityTables 41 false false R42.htm 041 - Disclosure - Stockholders' Equity (Details) - Schedule of restricted stock awards Sheet http://www.enzo.com/role/ScheduleofrestrictedstockawardsTable Stockholders' Equity (Details) - Schedule of restricted stock awards Details http://www.enzo.com/role/StockholdersEquityTables 42 false false R43.htm 042 - Disclosure - Income taxes (Details) Sheet http://www.enzo.com/role/IncometaxesDetails Income taxes (Details) Details http://www.enzo.com/role/Incometaxes 43 false false R44.htm 043 - Disclosure - Segment reporting (Details) Sheet http://www.enzo.com/role/SegmentreportingDetails Segment reporting (Details) Details http://www.enzo.com/role/SegmentreportingTables 44 false false R45.htm 044 - Disclosure - Segment reporting (Details) - Schedule of segment reporting information, by segment Sheet http://www.enzo.com/role/ScheduleofsegmentreportinginformationbysegmentTable Segment reporting (Details) - Schedule of segment reporting information, by segment Details http://www.enzo.com/role/SegmentreportingTables 45 false false R46.htm 045 - Disclosure - Contingencies (Details) Sheet http://www.enzo.com/role/ContingenciesDetails Contingencies (Details) Details http://www.enzo.com/role/Contingencies 46 false false All Reports Book All Reports enz-20180430.xml enz-20180430.xsd enz-20180430_cal.xml enz-20180430_def.xml enz-20180430_lab.xml enz-20180430_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 64 0000930413-18-001993-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000930413-18-001993-xbrl.zip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
7K[YS_\X./C;C_]V M>'CP"?D(6R%R#F:; _?T_X6K_W]P>' :K-8/MGMPZ8?TMW;H/B'Z,Y^N2_^; M_GX9ANL?CHZ>GY^_L>F?$MO%B 01MA%A/S@X/*0 #C(8IQ@Q"#\<7 ?^P4^1 M?W!\?'#\_H>WQS\O'M[_'WRS=]^]%S_\\PBZ(!NQ".C MWZ^O'NPE6EF'KD]"R[<9 .+^0.(?7@6V%<:D;<7KH/8OV'\=9G]VR'YT>/SN M\-OC;UZ(LT61_HT3;L'D%_CN*/GE&T:O@X,?<>"A>S0_B+?X0[A9HX]OB+M: M>PSS^&=+C.8?WR#_RR&C]-M_?/N6@?IW^H,_\9^4KR3P7(>QZ,3RV(X?E@B% M;P[8PH_WEX6]TF\"QN(C]LNCVF^/8OX#8O?GG861'RY1Z-J61[H@6UX*!/=+ M>@A7Z"&D_UY18++XEC\_2L^77B39L<=HB7Q"#WP"4A91WA(QLAI0?5A21BT# MSZ'J[?Q?D1MNIG2)=P'^5@3+AJ]U(5@@A$66%U[P+$W [#N*E :43BSBDF!^ M1_4SE9M8=XE@Q/M,V[FXH2OA]22]INBYVD1"*^3_71<=/0> \NQY5 ML-3JH#?HPIUYR"($A4(H-7VN3^U-;!M'R+ERK9GKN:$@N3A?'>FYA6_I_8,E ML:E\H^TDA(']N: JA<2]^I4FXB3W2&B]B KU[L^UD00MV('%:!U@JH060@0I M?Z/QGF'K4<->4%**'VCB"CT,012O>TP?1%]_"TI.W$D:[_59D24E9\X;C5?ZF-S51&*(U?[K3;" ME;62!&[\+S42COK83N2A8.ZFIW!C1Y@Y9S$H(1Q;EM!V'^3@.(C^CQLBC[H\ M_#,IB[G BA ;T8!Y/ZA&!,TCCU&'4'/:LNE!(2YS4E20;EM,%_JI3O1*FD=" MG58^U:3I=[0(F&Y4P;!M"?TR$#M_+(+FL! D\DGLI:(7]D^D@+? >OITL!C4 MV88NA:@>6.G>3WEEB)VQFRQ8,Z!K:JRHB!)_"?VBA!$)L6N'R(DA6L\6=E3P M;5@'0/Y+M['K4^VUBID\VZ2_5*&Y\+*ZML2)-9U1[\T5B^HV?*T+06[820+% MQN]UJ7"96),$[DKK]N(Q26Q"8!5M"K#J^4@@6O^QGNA@V?610*WN4UWR6_%[ M9(2T]F-=0=5M0$D"*\Y7NHA5TM$RI*KY5!-FA4"3!%K<[[HR[RRP([;9B>^< MT^7#S>7N+A-!JO'[%#D+VZ+XU;P'9\^Y["'XNQAOQUVQ][/ /Z1^H!5YX9N# M%$P>W^T:5*4=T4^.TK\YJG[>#Z[!RG)]9523KW=J& +9)5T"V]$,'6X!R^'+ M6R!WV8$0.";,X0JM9@A+4K?PZ=8:@L#2\CPYW-@'6XS2< >EYA6%7< *O83( M=Y"3X<4^5DE(R.2*0O,"NP#"8SD= -8,>1_?1.1P85GK/[=O[A0U=$G_ M2;@DBC.;M_1O8_G]P:;7#I6P M\\3"I6<@N1UWOZ?F+G(^O@FI59;;I"(W'FSD6]@-)B\NK! 5 "7*7SMKN+JT MD54%8>2RJ4B@*K?*W%#D1PKET:?.F.W.7>24WH)[2S2RJ _W_;.(F#^9/8=#(,8O5(6'3>=(B4N36+_^31Y7)G,2,@2 M12'XPP<$Q9NBN:5^]]20IYT=*KQ@26/42V'_Q_S?)\NC0,DD/+4PWE"_ZE?+ MBT#L #' F:%G@EN-8IIGF" -6U6>TEE*DB'(/;(1A4SOR1L4ICB#'*DF> 6= M,%Q^-=,,YIQER2&;&P3"E\+ZHS@U18JD5'^G]7#<8;2V7.<\>;D"/!5\0.8N M&F$FU% HY<:WL%<_^)5O6"$UBE_MC0]E&]_A@/I=X>;.LY+ )+VJULP8 =)( MC?!&IN+12&5B)Q[2^\AB-( ;>B1E"9"M3H?XXEVA049-2M@PLDVJ 0;R 7A41S&1.+'R[=X/B^I F363Y3A42RX8 M3=Q7F@8%*$1/B1IM EAY3JC02T&FJ&BWP89E1@6'R M6,@PHDH$8 Z&N:)4%# G%:,X62@8I.3TS_L M*B#L2>)V/K5>@"([4BB8M/TD#Z4L<7NR!_NQ TT_CZI)=K.!"&:)Y)P*ZB;T MP[)6F$8SH+JSKYVF0EEJ/QX5ZV-V]4;P=3/EWIC[,II]&%:E&50M007H)2%1?TQ*H0W];:*)4'V\3200 M;Z.0S6!PXH:[_? G#W*,3"J0#":W/1?4[?.^$@$[ KTG1+W61/F.?.OCBFH" M9S:&*LFFVKNI*1=>"X/@KJ8Z4&.P]FK)))(0KX4OP/=2([Q1(+J#FCE(\5M- HL(!S1EZ,\! &<.-<8PVP2NQ ,>930_1S9"$XI; MZN $."]X\R^#S:6%VXH,E<4$Y^@"R0A M\$U?#YS"K9N'*4.Z1T_(CZB/#9@H7H$Q].A>E2@P38TR.)!$-^RUULD7C]Q0 MJOQVS08M4P?X-"#Q*4P[RH *?3O0,803!$@GD%NL&/HAX>V<=<'(*\Z'P .* MRM5",U@*)BJXQ0A0/=U@SM<](HCNBO7P.Z-'V0OB%C\IKC"ZK0F@P>1O)8:U MD \L_^$!>1[K,Q//H?B-(52FM34?'*9 MIWL1X+,@FH7SR,O:0P Y,?7P1LB_9OJ)%#8KI8"CA>4Q6Q^"1;O%QZ880N M_*3KAKV98LLG%$=*HT]T=TQ=GK#1B BH4%4&O!DK0)Z74B0%*B#?W787=!=) MBY2(BE5Z'09^BD/R=U,VT._\A>Z(HN/Z%M[$NIXUR*%?4@IYL41"JEDX=/N/ M,JDH:D!VM5H[Z@)&,4EW=T(=\SE,6X(Z4&,(\]:2"'WBG1G/\7YZ5#\-/L$NH67T68?J_U!]V P>R*6!?C; MO3N[=V?-NK.)/+)S%/CQ( QHMY8+$(I7$/XMGV(P3E0)%IR'RP<$[SJ)N+9- M(EIXD> 3"V2^'A<6C&=;RQHCI=AZN2/JVW;L3 -7(UP%8M+?:E07-4UHA(NT M57@PQ<@B$=X G(762\/ MFBZ!PV9";6- W9?-_OU'\/U'>TEIP?:+6]Q.;'K>,$M[(>$U"I7JP6Q_HJ20F0R#6K",S%6 M,XLD^2* S?()0F:A9\T)]!W*34S/*W'H'ZC(=VJ0N)]BM@^16Q?\;2O M>&KFR;[B:5_Q]%HKGMCU&O<1I;?SR>:1L/E6V_Y^$VI)/%&:P38?5\!B!'$B M%=IJ'6 MOW"I<3TA!,%T/V^!:/1*[8NW;52'F9RS[W/?.Z.%6N,W#C10S^([*3_=@'@\ M?$A?@X*N([+N[#16C$ME!D>61Z5H]RKWC[?'G]/0/;ZV0GO)[<3,[5(@M=RK MULCRQ-6;P<;@EX+G68S\UH_[O-)MKBU_I_CQ*';C@@IG@2"B]/ M$J36GA3 XJ]5A?2 [ B[X>8,K0/BAEN+4R"L+;'8(!-_!)DG2S>H1"W!+9C5 MP,8ZX\I+MIHR%CJ8&CE\X?H6M?X,W[5-6(SWKFVD+4B#+(J!C9 33YUD&)/; M^2E&#LP-5 2Z*TP+RUY MZ&=H!G[T*O &:0QU.'Y5@L+X*3F0O?6I: ?ZVKC9W*9"[W4HCKU96\>HZRDL M]VH6#]A]>3Z?(SN\G9^_V$O+7Z![:JG=^@PK:HFS_V/.[I/E(:!,5RGX@R_R MEJ,F6$]0/L"D6+SL@D$P50K^X)DJ1TV1C#B-3)U0#8+QABH+L)8_8H"'WZQ% MD( "D]![:J+ )MN28'Z'$:&8)CG2RL_%9RYA&XDPFE(T3CS6M XP1-$$3OFR MB@ER.T_3,8!:[%:!F!1M ;;E99Q#(:'R\#[$F5H[;OPR2N&3-<*$I8PKSHPJ MSVN'%.5:6,IS<$H+;CG;!_8[8$9C%&T,+%A5]?0:C' _1.MUTL#$\ISMF9T' MF&1W4S"WZX4M%ZD'UR$-M+(HZ$%HA&%P]%R.J8K22Q4-&RR):D;DZY-+J?HR"'@'KR MJQ 9JOU%^G$IR_UF"0EKU"FIO-8%33RLN MUC%D:Q<(U-/Q447%J!DF( .E\5!JY!;-*NOC",79.,4#I-RZME@SD39N&D**G4P;:TV$3 6OT8&F1CDJW71W'K*_P M07506:>!,86E;H(0U.AK@=BQJ7EEX9X.C3APDR,+1'C=/!&OEJ0#.AY)14UH MO70("; 5IM9+7R&!>G!=*D/+BP*'!!K@F0X)M+*S5,[70+GAA 0>DM;7&*U9 MES-_H2CLZ3+WV3*@RK\.EG+CX=*"?:E[ ;!F8\ M3"UH>1$:#N;MY#2(GRJ1 M;W=QT%F]Y6ZE#:3,UX'JD-U16C(7I.]A WEHYHR9%@;FY;N)6H,1Z]TC_%W@ MN4RV3S;QOS:*:KVZ(&C;X'IHRHFDS[E%<>#3?]K)(U9"E^1_0=6\- Z&NVVV MLKR83RI+8+VS UB)5Q%L,CCI) JIE_$'"B=.L Z1T\AG;A6CRJI&V_0)\4V9 M7B#5BU2AVLSX3(;5N>1S4N[!_@7R\MX ;OBL$R*:2(5%SR_J\?P7Y??%U_"P M_F OD1-YB'6/3I=/.ETFLW%@G0Q1V$8]#B/!,TCCPD,N0APW.R$Q$3LPC+A14?//''RB4PK,)81D[OMOMK$F!U3:^C3 MT^75"MUHB:M<]HL,30<3LROG#71SE[[NI)>BMN125NV*:5G*W,6B+8U%CG1# M7KQR//2*/SV' MK<(>&*A#V^>-U>=&S)882V?:F&$VV)C"W7[2Z3[H >$GUT9\%/.;8,UQ%[[[ MA>XVKIJ/T>])0'4C:[1=@;H,:N<9S*"]'<)\#/.M5=+N*)L^U9TR5J/*$=3 M!$&7MZN S,JXW2.Z+]<.D1-C22VPTD\>?=9ETI3HZ,5WK!:2N/K MYD6..YMOQ_32TI?^/,"KF/,GF_27?1U%*53&D_6G2NO!A%^R'01TP?0IT<3JQI\+2AI"468/.[#\ M*4(:*7]*Y *;I;T%>(-@TX/8^B/E14R:0=FNN2LXRRGP6$X!-TM&N1JK,5WA M9'-M_17@4X]"NBJW]-,K00IX:,D\:T_7,)\F V4;6)Y7EWBF+A;J>3$\ R+P M0WINTA9+']^0Q&36E"ZSQNK61HE"&8@KE++XI -WR% !D24+&H4.GL)F:?JM- M@LNI1\L(!-3+N@#ES[?], *8"VAN15X(P09&(*UU!,P:NG+GZ,%VD4]-_^N" MQ=3@7G,^,OG*PCO,V:,\;W]@+VX7]1KP$PY@/-%6F&8G->JQ#]H)"_.ZU0!W M8MO1*O+H@78F*Q:T^Y+T>^Z7Q758&"Y' .=Z+?7!?.,&9("\Y1:(KYW%4HZV M?&EN3FJJ:=T0[&R!^"K8V495[0,TV!7?($-3;/G$2U(E=L.?.7:V&($%YF_HOG$O HSU-#K-/ ME&17_9O: @B92RCJX;(684CK,'4# ?/N$7)VA!I*4\]0:+D>J8=9$R[G:BH] M<-2JT+K YH3'M>^OWP"X=JYGVE@#F3L'QS4KZ[Q^@0J4RX 'C,:V1LZUGB1! MW5RE/U XMP&''08WU@K!Q=UE48 +C@G%Y15.C2#3^01O97P/;(>)\RLQWNAC M0+^\%WH\4#SW=U;(/ '>\X&N$N(\ +,-OA257&$N<)%>0-KXE'IHP0KA>Y08 MXF3IK@%YU 3.Y!.$!GXU4E+OPP.S#WY#,T)1CJNV_Q6YF"7=^TQBA-_GVE88 M*3^$B-/^ "#_1&I3?8Z<*;*7?N %BPV%'I?X2CR8MBPQ6ITF1B"!,/[??ORW MP\.#__GM^M=__.___&ZOHY<__.\^.%_>/RW^V/B/9]'SI_?XP_N?W_WU.-T0 M[_V3_>6M]U-X=/?'R]7ES=%W-_]U_?+=\O$7;W*VO/EK]>Z_[8=/1ROOZ.J[ MQY^MOY;?DS/K?/HX_>5J\GGUW:=O;YX^__WJ[^'3N_?AV4^;E^CA\H^+[__Y MX9]K_.&?R\FIL[3LDZO0^^7BTZ_1$_G]G?WT>/9\\^[%>GBY#Z/WCW>_>&]_ M^N7GG]#FW0V^"\^/SK^\+'\)SG]_>W/\X>'1^G;A?7FY.PK.K>F'WW]Z^_(T M.?4?OAR3<&U].3H]_>Z_9G?37SI]0@0B_$M%&]7[VO.P7R\DI$/E':.5"?L7C=?SHB%XXO9O&_NW MC?W;QOYMP]3;!L'AG_>LP9>@?J=_GV,H_:\R,XL+ MWT)K5UB6+:O>KM^L)A M+'&>]!"%;=297&DK$!7HL:BTOI#^4B*K 64D2E3M=55L_6NZSU6TTBNKQ46- M^.TUIS C:VG;NNLW8Q#6"P!E"XL.DK+%;4.]Y>]?C?M\-=8TQBL#&;^Y5? % M8UX3N)$SKY&2?=<:9G,+YB M)H3@FFDZ!1BCDJ,ZE+;-TGJ<9J(5^I-+STZBY&].B5"HD-?P\?*,;JL M97)\XQ;63AL\01R9=J!FF0.]P,$>$>="6=X% CTD+1&-WA]P1::.;]NX#.13O$4%T4\N)[YRA M)^0%:_;DU>7("*\X= VF1"6Q) U'ZR*-N#1:H$XDJ/51C?MK0-*9[H?7HV> M3>T<:BW_[S>O)F!RQ;%W9;5P>:93Q;,H ZKX$PT*N.*B$U]*]4TG57@;\($5Z=H5DXI7\/E;S"A0/'9:%GSVY"G]>! M?"I"]:HL0X-+,*F!9#B/I$EFF[@"W+N2#PXF :2),4;S/+KQ1OO#Z_;IQ5J[ M(76GD470[4P5[L#P<6_SAP"5WSH=F:13$JU^T9J+:C;&. N?MY&&8B MG'J,Z'K""9R WGU)LAV#9N?&H*$7]D^T>TB1GWE4&N5 !9MA_U7ITN#,8 MJN2%\FGSD.#\60Z4X4QBJ)/E@DW.(5-_+('Q96N8,H2I#&HL$:L^D [1KFM= M5G[D=3T0C[/^:&^#IFMISU*:?*5!M.)TK/G0K*_33M.Z_4(EKFVGD\>3I9]] M>BDMF.O9IG6A*)J-O)N MM)<>C'J8D*<3T1X]/V#AY(_9T\I44W[AI4^5!=J:;U81,XL#V. FU@>H@1=@U$.$7=IK8N;^=G](?N[;E75FS +._W*2*1-R)$ES(Z. 4 962.5>B= %1?@_( MHS]>?$+4L+<\UO?465%$6(9>Z#ZAU*8'?-N60\#P\"-!KBH2%Z;P+[V*J>O. MO:D!'6A!R&:#'SW8Q:(<$-6Z/?O.S/$/XJ#:FGK]RAFN.PLR"27$*[(X@DQ= ME\ B'1Z"^+S'F)7-QW-U-[L_N;,V[$>39PL[:B;ZGT.)((Z&0LV MASG>\24A$7+.(DSU;H)-C#C)D8-D"#D@4B:/A;%Z/45I4:"S0,FE$8V4H3A> MI22W@[&)6L_\%:@[-6&-578Q#4++N_1#>OJ(:_]J>=$@?0,AO%^;2&KAI< @ M;!.">!'@.7+#B"KZB>^QF^(5J/K*DT7M,QZ1J#\UAW;P--YC)[AQSN.UL5R:_I MG8W#HDR:] ]"U(CLV$Q%4=2_M@<0899F4ME0JF_"_JO'O\XJ.!ZB_:>RC:_, M_E/B=":UC0\FAN6V:$T,73S+V'Z]4ECA6R9LC;TQ>T]+P]N2Q#A!S6*;T9"; M5JITC&FDEJ#6O)*!O**D-)"UK,%1_$X2=T69+BT_%8*;P'^B2"-G@%:U-/(# M.,!"LJ3%ZI%G+5#;NAYV4+HEXS2#,RM$%Y:+AQ=LT+DO\T\20Y1H 7G07LX" MO[U?X[T-\@E-%G?CX;0!26V9K>V-XH8LEJ],%NOW#] M>8!7,7UFF_27*J&?79UNO,1]MO[E;OTKR&X\0G!5"S-V<<1Z*%2D\M2#V*(" M&D /I;6M<638S^]W(T'B[MUL9*2!C7:^PX$3V>$M3DNT<>!.,>_[U VL3YVFP\G"IG&]JW#_Q_Q?FWC!D*9S98L0\]?V M[36UM-?4TQXG!JR!%2),Z/\ " 6NMO07I;SFRSY%$.Y&* (8."=JJ*)_LLQ] ML+&\<$.1N:*8T&OC DD(?-/7 Z=PZ^;U.B&EHZ6D4P:@RKF!(8[J@)WG<^7. MT8/M(E]&.7,^&BHA>?L#Z?$]75(+D>/2$_ M@AE>O%W;;$]QU82"'6E@6L$GKM"G('#RILQ#X($D,C9 Z[\4OBMKFD@'=@'< M(X+HWI84XAD5#2]8,]P!._8W S2OOA1.5",%-=\5 M_CPP(SPA7&H!=0R\]$/$>AHDH%)1N$$A!'MJ88V01_5T VJ2%P<=;@(_* H' MH%'7 M'H6[/RT6JAHDCO.37^4=L#N0O_-,(8^?9FBBV?6#9#^!/=+#OC)XCN M 4VM%PAFRH ?IY4G16"1KG#JJ3X,V 7=%.N@Y/H1W42JT@,_12+Y.XH*(M>N M'^"XDBK1*/1&+JZ2%%I=HW 9T-^P[@-QX!%&0_>'_@"BO I:OT?V O6(.T-K MC&PW25U :P_%=*=>[8K1XDO\_6(5P#0^,(JLHI*W5+\LI$I9$;%O?"R.TE0I?26)G M[Z&M).A>Q*L83_-M5@"C8$')OKJX M=Q6JH8IX7T:\+R.68L2^C+C"!LM#),T9NT& E0Y\0.9"1**&5($E?&)I;>BR MS\F'-K?NZ'7&+JD%S$"!1GCF9JA(NK!BU!-*,>TCM$)/HQL'XBE\0NT5PH)] MN^"*?+IVTX(R 1:Q=10K)9H6%PVTM*\!I46XD18INF?Z1( ._;9,JUSZIYY% M2#J. ]P]J "#>]T7<@Z$Q93K'E1)!Q5:R0$"#*94H0S'1:@3T\*-P"&3R.6M MAR5 P1$^4X;@+JBQ1"SL(=O@[IZUD=79^G&W() CH%\_E>B@.;:T75W8$1.G MY E .BODYG0K*!+^ MIP.7[OHM:^W5M,TV\T/7<;V(I2 ](#O"E!J(G+_87N0@)\DS7:VC)/YV.S^W M,!O.2NX0CM/3)BM6QP;AX>A!S-!$#.F@D&9VB![&7B9:1.MU$K.R/,.Y!40_Z;6E!IZH:L4_ EO12>7">R/*B +!^0R4A'YQ.05ZXU= 2*SE:@ M_>:&RWOD)94:2W<]#CW/HF H1 _,E337\?538[D=K;22]IRR<7KF_Y-G)X M+GU--+QQ@?XSY;0["VTD:NVDI9:"$=B?+PF)D'-&_7]_DT_(4[\Z@(LTKP?"ZPM&W7OJY, MY%MF-15+M'U]T:"VZ$IPI@HW@JW CLP$%::-CNCTOJBP6[1:4I#EBPM!:]I MF+4O+=R7%FIF UAIX>F2)7E=^FEW7FI(G)/075%<3S93^CU8MPD1N"9?X3KH M-3&:@H4>Z\$SX(!%$R)PH;PNL1X4$L(NQM \1:$J7@2 Q5<"#+4;#\*0)Z" MY&/OZX;U/K.DJCGI)9;O 9AXQ'#/E\*PS69?2MP&I:<80N-7.]."VW$*)3[;7)#&WO+(9,9&N]@@.=5-X)025#.: ML*$:#R@,DUA3T@1;Y FY^7NC=X4 :[);OH4*HA=^'T(<=Z"O$6'EN0"Y]=B8 ML.25-)K]A>QP&EQ3]1 /0+Y'#EK%SZ:0(MX-(=7 @;5V0VKE4>V'R$441AA= M4X:MHE76]C4WL"'.Y+_TL]^ ."M=\#%ZZK3(4\&UZ<0:L#8!.:QN9YZ[2%+K MH&4A#\ILBB$HGPL4!1HJR0?'O?E ^3B(N[(O;I:OU":K4(FM5X&_F"*\.D,S M$"86UC!1?$@R MG$3=S8JS3>K6JSBG3<5R[8NH-4RH75BXC*]Y :#( +].3YC2VV*\EMUWSFG8 M5]O)5=L)2:..DKI]05T?;WS[@KI]0=U "^JV*2")GF%=#0*_E[0Q+D"C:6/R M:K>%>B*O("I,*T&#T[-\0$;S)80$-L^C&F*!7(U<6##*L98UP\@HZ\0=P=D; M:D\]GN7?6"NP)++"^F;'$\GKLR)Q]-8ZEF' ::T2A!Z2+!OT%4_>>"07M^BZ M$QU&(W'(;E07R5%>5.>H=?=ZMK #F;I:! !H" ,IGA*!6N.6BL8N=Y+G!&.6 MCA0_-9UL=G^3/C_%J.WP\QUX!0:"IUDUR#T!!5,:A#=0A0( R +5&T")DE'5 M;D2:P.H=!+K'ZA&&VC:SIG)V ?5Q7AI4.]3*OR-,GX/I,HB(Y3OG'IOWQ) 3 MSJAN^MILGD ]C5MW#99GO>\%-<1>4/0DKP(?6)%5@9A\Q&\,QQ5G8E5H _-" MD^^_ ,<%'AB#+_3";."2!VC6:X[E=Q:^Q7& +&F)D#4+!CX@M6#-]0F2>J"6 MHJ1F+C)L=W/K;N<,!Y)H#KW$>?E1N RP M^R4V\[,S/%U:X;6U.4%)PQB63D7WH\:OC@#,U5O)\[$K+5L3S*0SI[;=\;=8 M;(%/ETB&C<)+C44IBM.FO=>9ZO/^OHEA'\9)ATZ%]?W/]GT*>^6A2#/"AE9E M.MBU[T>HB7UM30>_UZYHVT*9=9',FX@1X7:>"MSV>C?R&""-Y)@$!(!%J31] MT"U-YR\V(F1JO:3M$MG (3[Z22MD>N%,[-!]BFT-D&RC3@B-24HZDCX+0.@/ M=V<=-!\0?J+.&Q^GFR =RA<++ID&H>7E?\]4X4T0_H'">V0'"Y^)<=X\ 9&= M7A ?E8SUP\I,%O7GLX!M(#&;+P*<_HC]W?&HA)*_@Y&Y,WWS-Y-4[86D<"=M MNU+R45P>2+U\?Y2*M&TS>^4JQ/),C)N"IPJUB:IV:T(S-CP#1W$V11GC+15R MPTY+(V;O$6,1_?EIX,>EK)'EL:I5H6K-82(^!F$>,/FV4JY_Q$:\G5G[CF?E M':?[^C7>U&7:"^["AQ&=_JEB9PQ MNR'0WU,CE62^8\CF.ZIV^4MFX)67J5"L<49@_=>*;DEU2=%>*75?0N4.OWVP(L_S^1RQ]!J4W'(4Y#U% M@#W*^;;KN4D4,+Q %+SEL7,8K5@):I<)N@YZN5 T#5=3LH!72V M<@UB ;8#-1=>D^2M /V@6GSSQ8J]-KI^Y/J+6VKYPG7CEX ^ZF/*IR=0>YTM MY/,7]D*3!61!SV )U/A.7IE6 AW >VL!GD0O,5JS,6O^HNN0FG2]^VP]R/DS MM;!47:7L'3%9D3G8V;!<"/0;H!ELU]+"O[Q\-Y%++.C:AX0GZG&!Z-6G8XS8 M54#(;LD-I'S7@5)\S,G8=8?B9*!3-J5'P*GA?F9.0%OHG_DQ_,WJC; P."5T M,K WZ/D,S2ELJZ(\N$066L9D_Q-!LHN10\Q3Z$,YG 5VG#XW\9VDM^<<0-RTM2N7;I_XT.6\/54:7?+U?1WKE-(DC&52_O6ILT;@0R?*R*4:G?- MU?AS%\T\U[[P HOC*BBR([_F"+01AQ B+5&D"3ZA"#D,J0O/TB'[Q?5&<:^6 M2-#:A429Q&>(V-B-D_QU4CJ_[!AL1CX]!/J)*"I[%K&SO$OJZ+S\C#;Z]'MI M73.15D6U7J:)[BX@.5#)[;Z-D<4/8CJ\N\;E1Z%XF@G4VDI#C1^_!E[DAQ;> M7+@>POH845YW3,>A0A/]32MVP&(8I]2^7018GS8JKCH6\[)$"Y'^#&I$_PUY MWL]^\.P_((L$/G+BV@E.VI B^>O6'PLC:NDCTHA -="0U*SH\X'YZXY#$=70 M1'\!?1[8SN6^H#_1&7(MKSR*^[B6+ (%WMU8D'4!@6!"?NTQN <-E!&H?VYZ M#/GQB %B9=>,8?\'4$L#!!0 ( #2+RTP7O+0!^UT !S?! 4 96YZ M+3(P,3@P-#,P7VQA8BYX;6SM?6MSY+:QZ/?S*W"=6RF[(GDE/^+83LZMT6NC M1"LITJP=7UCN]%H-!K= M?_X_+]L(/,,T"Y/X+Y^/Y]?7G_R?_P;@O_[\ MOXZ/P5L8P]3+80">]B \_S3??@:.P7FRW3WZ(;B.<_1;/P^?(?I9C."B?Z/? M;_)\]]V;-Q\^?/C<1Y]F?IC"+"E2'V;X!^#X&"$ %8[S%&(,WX%W20S^5L3@ M]!2EWI]^ RXLE^.+D]$]TS'_].0KC7Y^\# (TD3C[RR<-5"]/:?1Y MDJ[??'%R\N6;ZL-/Z)??O> ?M+[_\"7Y^O3;;[]]0WY;?YJ%K \1V-,W_WQW M\^AOX-8[#N,L]V(?(\C"[S+RPYO$]W+"6BE=@/L%_M=Q]=DQ_M'QZ1?'7YY^ M_I(%GQ#&_1< ?TZ3"#[ %2"4?Y?O=_ OGV3A=A=A@LC/-BEHSD6XSD](\8R>_*']]X3S#Z!. OWS]<<^?T;0L6'?3&)IU+I,_0B-C& MR-$ISOO4YKI$Y@?:,&41_M<-HJ!%&WS)81S H*(.CQ4H( %-U+V:,8:<^"V8 M$5;D)*U $L1_^:3(CM>>M_OW8XZ8MX5Q?K>Z"F.T"$(OND^R$*O^XBG+L4U@ M\HI0LO*R)T).">X-7M]O8)1GU4^.\4^.3TY+I?^=%E[$K').F.C6K"HKI,4I M*C)C/OP[>HJ(84&#L9&%\?'[QT_^NQX*DA6H!X-J-/BY&O^O/U,2_OL@*_S/ M1=H6F)?Z%9'HKY*)E5^\\1-DOW;Y<6N.JS39FHDZ3PQ8\\98"\^];+.( _S' MY7^*\-F+$+ILD9][:;I'&]H/7E2PE^Q -51#_*8CL4DU48DDCBKB0<"+ ^#C MO\##\(/F.5 \+>DV-4^=%2-;BAU,PR1 BI]6=GZ8J$YT9(6\KB>X#N,80< F MA1)32_"C%.!)M3&.+,++.!A%@*>: D2[.$-T'^GJ.VT*3\ON+WP_*1#0!^A# MA. I@K
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Ð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end